PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 1A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO
CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION STUDY TO 
EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF 
PF-07321332 IN HEALTHY ADULT PARTICIPANTS
Study Intervention Number: PF-07321332
Study Intervention Name: N/A
US IND Number:
EudraCT Number: 2020-006073-30
Protocol Number: C4671001
Phase: Phase 1
Short Title: A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study of 
PF-07321332 in Healthy Adult Participants
This document and accompanying materials contain confidential information belonging to [COMPANY_007].  Except as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes
Amendment 3 24 June 2021 •  
 
 
 
 
 
 
  
Amendment 2 02 June 2021 •  
 
 
 
 
 
 
Amendment 1 05 March 2021 •  
 
 
 
 
 
Original protocol 28 January 2021 N/A
This amendment incorporates all revisions to date, including amendments made at the 
request of country health authorities and IRBs/ECs. CCI
CCI
CCI
PF-[ADDRESS_1145265] OF FIGURES ................................................................................................................ ...9
1. PROTOCOL  SUMMARY...................................................................................................10
1.1. Synopsis .................................................................................................................. 10
1.2. Schema .................................................................................................................... 18
1.3. Schedule of Activities .............................................................................................19
2. INTRODUCTION ...............................................................................................................3 4
2.1. Study R ationale .......................................................................................................34
2.2. Background .............................................................................................................34
 
2.3. Benefit/Risk Assessment.........................................................................................41
2.3.2. Benefit Assessment.....................................................................................44
2.3.3. Overall Benefit/Risk Conclusion................................................................44
3. OBJECTIVES AND ENDPOINTS .....................................................................................444. STUDY DESIGN................................................................................................................ .47
4.1. Overall Design.........................................................................................................474.2. Scientific Rationale for Study Design.....................................................................524.3. Justification for Dose ..............................................................................................55
4.3.1. Justification of Dose for PART-1, PART-2 and PART-3 (Original 
Protocol, 28 Ja nuary 2021) ..............................................................................55
4.3.2. Justification of Dose for PART-4:Metabolism and Excretion 
(Protocol Amendment 2, 2 June 2021) ............................................................58CCI
CCI
CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 44.3.3. Justification of Dose for PART -5: Supratherapeutic Exposure 
(Protocol Amendment 3, 24 June 2021) ................................ .......................... 58
4.4. End of Study  Definition ..........................................................................................59
5. STUDY POPUL ATION
......................................................................................................59
5.1. I nclusion Criteria .....................................................................................................59
5.2. Exclusion Criteria ....................................................................................................60
5.3. L ifestyle Considerations ..........................................................................................62
5.3.1. Meals and Dietary  Restrictions ...................................................................62
[IP_ADDRESS]. Dietary  Fiber Supplementation (PART -4 and PART -
5 
only)...................................................................................................66
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................66
5.3.3. Activity .......................................................................................................66
5.3.4. Contraception ..............................................................................................67
5.4. Screen Failures ........................................................................................................67
6. STUDY INTERVENTIO N
..................................................................................................67
6.1. Study  Intervention(s) Administered ........................................................................67
6.1.1. Administration ............................................................................................68
6.2. Preparation/Handling/Storage/Accountability ........................................................70
6.2.1. Preparation and Dispensing ........................................................................71
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................72
6.3.1. Allocation to Study Intervention ................................................................72
6.3.2. Breaking the Blind ......................................................................................73
6.4. Stu dy Intervention Compliance ...............................................................................73
6.5. Concomitant Therapy ..............................................................................................73
6.5.1. Rescue Medicine .........................................................................................74
6.6. Dose Modification ...................................................................................................74
6.6.1. Dose Escalation and Stoppi[INVESTIGATOR_1869] ................................ .......................... 74
6.7. I ntervention After the End of the Study ..................................................................75
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................75
7.1.Discontinuation of Study  Intervention ....................................................................75
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......[ADDRESS_1145266] to Follow -up ....................................................................................................78
8.STUDY A SSESSMENTS AND PROCE DURES ...............................................................78
8.1. Efficacy  Assessments ..............................................................................................80
8.2. Safet y Assessments .................................................................................................80
8.2.1. Phy sical Examinations ................................................................................80
8.2.2. Vital Signs ..................................................................................................80
[IP_ADDRESS]. Respi [INVESTIGATOR_82218] ........................................................................81
[IP_ADDRESS]. Temperature ..............................................................................81
8.2.3. Electrocardiograms
.....................................................................................81
[IP_ADDRESS]. Continuous Cardiac Monitoring b y Telemetry  (PART -
1 
and PART -5 only ) .............................................................................82
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................82
8.2.5. Pregnancy  Testing ......................................................................................83
8.3. Adverse Events and Serious Adverse Events
..........................................................83
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......84
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety ...............................................84
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................84
8.3.2. Method of Detecting AEs and SAEs ..........................................................85
8.3.3. Follow -up of AEs and SAEs .......................................................................85
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................85
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................85
[IP_ADDRESS]. Exposure During Pregnancy ......................................................86
[IP_ADDRESS]. Exposure During Breastfeeding ................................................87
[IP_ADDRESS]. Occupational Exposure .............................................................88
8.3.6. Cardiovascular and Death Events ...............................................................88
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_1145267]
.............................................................88
[IP_ADDRESS]. Lack of Efficacy ........................................................................88
8.3.9. Medical Device Deficiencies ................................ ................................ ......88

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 68.3.10. Medication Errors .....................................................................................88
8.4. Treatment of Overdose............................................................................................898.5. Pharmacokinetics ....................................................................................................90
8.5.1. Plasma for Analysis of PF-07321332 PK, 
19F-NMR measurement 
and Metabolic Profiling ...................................................................................90
8.5.2. Urine Pharmacokinetics (PART-2 only) ....................................................918.5.3. Urine and Feces for Measurement of Drug-Related Material by 
19F-
NMR and Metabolic Profiling (PART-1: Cohort-1, Period 2 only)................92
8.5.4. Urine and Feces for Measurement of Drug-Related Material and 
Metabolic Profiling (PART-4 only).................................................................92
8.6. Pharmaco dynamics..................................................................................................93
8.9. Immunogenicity Assessments .................................................................................94
8.10. Health Economics .................................................................................................94
9. STATISTICAL C ONSIDERATIONS ................................................................................94
9.1. Statistical Hypotheses .............................................................................................949.2. Sample Size Determination.....................................................................................94
9.2.1. PART-1: SAD.............................................................................................949.2.2. PART-2: MAD ...........................................................................................959.2.3. PART-3: Relative Bioavailability/Food Effect ..........................................959.2.4. PART-4: Metabolism and Excretion ..........................................................959.2.5. PART-5: Supratherapeutic Exposures........................................................95
9.3. Analysis Sets ...........................................................................................................969.4. Statistical Analyses .................................................................................................96
9.4.1. General Considerations...............................................................................969.4.2. Primary Endpoint(s)....................................................................................97
9.4.3. Secondary Endpoint(s)................................................................................97CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. PK Analysis...............................................................................97
[IP_ADDRESS]. Statistical Methods for PK Data................................................99
9.4.4. Tertiary/Explorat ory Endpoint(s) .............................................................100
9.4.5. Safety Analys es ........................................................................................100
[IP_ADDRESS]. Standard Safety Analyses........................................................1009.4.5.2. Electrocardiogram Analyses....................................................101
9.5. Interim Analyses ...................................................................................................102
9.6. Data Monitoring Committee or Other Independent Oversight Committee...........102
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ........................................................................................................103
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations .............103
10.1.1. Regulatory and Ethical Considerations ..................................................103
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.......................................................................103
10.1.2. Informed Consent Process ......................................................................[ZIP_CODE].1.3. Data Protection .......................................................................................[ZIP_CODE].1.4. Dissemination of Clinical Study Data ....................................................[ZIP_CODE].1.5. Data Qualit y Assurance ..........................................................................106
10.1.6. Source Documents..................................................................................[ZIP_CODE].1.7. Study and Site Start and Closure ............................................................[ZIP_CODE].1.8. Publication Policy...................................................................................[ZIP_CODE].1.9. Sponsor’s Qualified Medical Personnel .................................................109
10.2. Appendix 2: Clinical Laboratory Tests ...............................................................[ZIP_CODE].3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ....................................................................113
10.3.1. Definition of AE .....................................................................................[ZIP_CODE].3.2. Definition of SAE...................................................................................[ZIP_CODE].3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.....................115
10.3.4. Reporting of SAEs..................................................................................118CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 810.4. Appendix 4: Contraceptive Guidance .................................................................120
10.4.1. Male Participant Reproductive Inclusion Criteria ..................................[ZIP_CODE].4.2. Female Participant Reproductive Inclusion Criteria...............................[ZIP_CODE].4.3. Woman of Childbearing Potential ..........................................................[ZIP_CODE].4.4. Contraception Methods...........................................................................121
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ......125
10.7. Appendix 7: ECG Findings of Potential Clinical Concern .................................127
10.9. Appendix 9: Abbreviations .................................................................................[ADDRESS_1145268] OF TABLES
Table 1. PART-1: Single Ascending Dose Cohorts ...............................................19Table 2. PART-2: Multiple Ascending Dose Cohorts (Including Optional 
Japanese Cohort).......................................................................................22
Table 3. PART-2: PK Days (Day 1, Day 5, Day 10) in MAD Cohorts..................25Table 4. PART-3: Relative Bioavailability/Food Effect Cohort ............................27Table 5. PART-4: Metabolism and Excretion Cohort ............................................29Table 6. Provisional Dosing Scheme in Part-1:SAD..............................................48Table 7. Randomization Sequence in Relative Bioavailability/Food Effect 
Cohort .......................................................................................................50
Table 8. Provisional Dosing Scheme in Part-5:Supratherpeutic Exposure ............51
 
 
Table 11. Probable 90% CI with 80% coverage probability for Varying SDs, 
Effect Sizes and Sample Sizes – in PART-3: Relative Bioavailability...........................................................................................95
Table 12. Plasma PF ‑07321332 PK Parameters For PART-1: Single 
Ascending Doses, PART-3: Relative Bioavailability/Food Effect, PART-4: Metabolism and Excretion and PART-5: Supratherapeutic Exposure ...................................................................................................97CCI
CCI
CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 9Table 13. Plasma and Urine PF ‑07321332 PK Parameters for PART -2: 
Multiple Ascending Dose s................................ ................................ ........ [ADDRESS_1145269] OF FIGURES
Figure 1. C4671001 Study  Design ...........................................................................18

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 101.PROTOCOL SUMMARY 
1.1.Synopsis 
Short Title: A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study  of 
PF-07321332 in Health y Adult Participants
Rationale
The current study  is the firstclinical administration with PF-07321332. I t is a 5-part stud y 
combining PART -1: SAD, PART -2: MAD ,PART -3: relative bioavailability /food effect ,
PART -4: metabolism and excretion (M&E) and PART -5: Supratherapeutic E xposure (SE). 
PART -[ADDRESS_1145270] of an oral tablet formulation .PART -2 of the 
study may also evaluate the safet y tolerability  and PK in Japanese participants. PART -4 is an 
open -label, non -randomized, single period to evaluate the metabolism and exc retion of 
PF-07321332. PART -5is a double -blind, sponsor -open, randomized, cross -over stud y to 
evaluate safety and tolerability  at supratherapeutic exposure s. 
Objectives and Endpoints
PART -1: SAD
Objectives Endpoints
Prim ary: Prim ary: 
To assess the safety and tolerability 
following a single dose of 
PF-07321332 alone or in combination 
with a PK boosting agent (ritonavir) .Frequency, severity, and causal relationship of TEAEs and 
withdrawals due to TEAEs .
Frequency and magnitude of abnorm al laboratory findings .
Changes from baseline in vital sign measurements and 
12-lead ECG parameters .
Secondary: Secondary: 
To assess the plasma PK profile of 
PF-07321332 following single 
ascending doses of PF -07321332 
alone or in combination with aPK 
boosting agent (ritonavir) .Plasma PK parameters of PF -07321332: 
Cmax, Tmax, AUC last, Cmax(dn), AUC last(dn).
If data permit, AUC inf, AUC inf(dn), t½, V z/F, and 
CL/F .
Tertiary/Exploratory: Tertiary/Exploratory: 
To explore metabolites in plasma, 
urine, and feces, if data permit .Qualitative characterization of metabolites of 
PF‑07321332 in pooled plasma, urine, and feces ifdata 
permit.
Quantitative excretion of drug -related 
material using 19F-NMR spectroscopy , 
if data permit.Total excretion of drug -related material in urine and feces 
separately, and both routes combined, expressed as a 
percent of total dose administered , if data permit.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 11To determine the oral bioavailability 
of a tablet formulation of 
PF-07321332 relative to suspension, if 
evaluated (Optional) .The ratio of AUC last, AUC infand C maxof tablet formulation 
and suspension .
To evaluate the effect of food (high fat 
meal) on the exposure of 
PF-07321332 follow ing a single oral 
dose of PF -07321332 tablet 
formulation, if evaluated (Optional) .The ratio of AUC last, AUC infand C maxunder fed condition 
and fasted condition .
PART -2: MAD (including optional Japanese cohort)
Objectives Endpoints
Prim ary: Prim ary: 
To assess the safety and tolerability 
following multiple ascending doses of 
PF-07321332 alone or in combination 
with a PK boosting agent (ritonavir) .Frequency, severity, and causal relationship of TEAEs 
and withdrawals due to TEAEs .
Frequency and magnitude of abnormal laboratory 
findings .
Changes from baseline in vital sign measurements and 
12-lead ECG parameters .
Secondary: Secondary: 
To assess the plasma PK profile of 
PF-07321332 on Days 1, 5 and 10 
following multiple ascending doses of 
PF-07321332 alone or in combination 
with aPK boosting agent (ritonavir ).Plasma PK parameters of PF -07321332: 
Cmax, Tmax, AUC tau (where tau=8 hours for TID 
dosing or 12 hours for BID dosing), C min, Cmax(dn), 
AUC tau(dn), Cav, Rac, Rac,Cmax ,PTR,CL/F and V z/F.
If data permit , t½.
To assess the urinary PK profile of 
PF-07321332 on Day 10 following 
multiple ascending doses of 
PF-07321332 alone or in combination 
with a PK boosting agent (ritonavir) .PF-07321332 urinary PK parameters: 
Aetauand Ae tau%, CL r.
Tertiary/Exploratory: Tertiary/Exploratory: 
To explore metabolites in plasma if data 
permit .Qualitative characterization of metabolites of 
PF‑07321332 in pooled plasma ifdata permit.
To explore PK by [CONTACT_825894] (s), if evaluated (Optional) .Concentration of PF -07321332 , if evaluated.

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 12PART-3: Relative Bioavailability/Food Effect Cohort
Objectives Endpoints
Primary: Primary: 
•To determine the oral bioavailability of a 
tablet formulation of PF-07321332 relative to suspension.•The ratio of AUC
last, AUC infand C maxof tablet 
formulation and suspension.
Secondary: Secondary: 
•To evaluate the effect of food (high-fat 
high-calorie meal) on the exposure of PF-07321332 following a single oral dose 
of PF-07321332 tablet formulation.•The ratio of AUC
last, AUC infand C maxof tablet 
formulation under fed condition and fasted condition.
•To determine the pharmacokinetics of 
PF-07321332 following oral administration of tablet and suspension of PF-07321332.•Plasma PK parameters of PF-07321332: T
max,Cmax,
AUC last, Cmax(dn), AUC last(dn), if data permit AUC inf, 
AUC inf(dn), t ½, CL/F, V z/F.
•To determine the safety and tolerability of 
PF-07321332 following oral 
administration of tablet and suspension of 
PF-07321332.•Frequency, severity, and causal relationship of TEAEs 
and withdrawals due to TEAEs.
•Frequency and magnitude of abnormal laboratory 
findings.
•Changes from baseline in vital sign measurements and 12-lead ECG parameters.
  
 
  
PART-4: Metabolism and Excretion 
Objectives Endpoints
Primary: Primary: 
•To determine the extent of excretion of 
drug related material in urine and feces after a single oral administration of PF-07321332 with PK boosting agent ritonavir.•Total recovery of drug related material in urine and 
feces separately, and both routes combined, expressed as a percent of total oral dose administered.
Secondary: Secondary: 
•To determine the pharmacokinetics of 
PF-07321332 following oral administration of PF-07321332 with PK boosting agent ritonavir.•Plasma PK parameters of PF-07321332: T
max, Cmax, 
AUC last, if data permit AUC inf, t½, CL/F, V z/F. CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 13To determine the safety and tolerability of 
PF-07321332 after a single oral 
administration of PF -07321332 w ith PK 
boosting agent ritonavir.Frequency, severity, and causal relationship of TEAEs 
and withdrawals due to TEAEs.
Frequency and magnitude of abnormal laboratory 
findings.
Changes from baseline in vital sign measurements and 
12-lead ECG parameters.
Tertiary/Exploratory: Tertiary/Exploratory: 
To characterize the metabolic profile and 
identify circulating and excreted 
metabolites following administration of a 
single oral dose of PF -07321332 with PK 
boosting agent ritonavir, if possible.Metabolic profiling/identification and determination 
of relative abundance of P F-07321332 and the 
metabolites of PF -07321332 in plasma, urine, and 
feces, if possible.
PART -5: Supratherapeutic Exposure (NH CRU only)
Objectives Endpoints
Prim ary: Prim ary: 
To assess the safety and tolerability of a 
supratherapeutic exposure of PF-07321332 
with a PK boosting agent (ritonavir)
administered as split dosing.Frequency, severity, and causal relationship of TEAEs 
and withdrawals due to TEAEs .
Frequency and magnitude of abnormal laboratory 
findings .
Changes from baseline in vital sign measurements and 
12-lead ECG parameters .
Secondary: Secondary: 
To assess the plasma PK of PF -07321332 
ata supratherapeutic exposure of 
PF-07321332 w ith a PK boosting agent 
(ritonavir) administered as split dosing.Plasma PK parameters of PF -07321332: 
Cmax, Tmax, AUC last
If data permit, AUC inf, t½.
Overall Design
The study  will combine PART -1: single ascending dose (SAD), PART -2: multiple ascending 
dose (MAD , including optional Japanese cohort ),PART -3: relative bioavailability  and food 
effect cohort ,PART -4: metabolism and excretion study and PART -5: supratherapeutic 
exposure cohort .PART -1 and 2 are randomized, double -blind (participant and investigator 
blinded), sponsor open, placebo controlled, single and multiple dose escalation study .
PART -[ADDRESS_1145271] .
PART -4 is an open
-label, non -randomized, single period to evaluate the metabolism and 
excretion of PF- 07321332. PART -5 is a double -blind, sponsor -open, randomized, cross-over 
study  to evaluate safety andtolerability  at supratherapeutic exposures to be conducted at NH 
CRU only .  

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 14PART -1: SAD
SAD will include 2 interleaving cohorts with a total of approximately  12 participants planned 
(approximately  6participants in each coh ort), with 4-period cross - over in each cohort. 
Period [ADDRESS_1145272] (high
-fat hig h-calorie meal) , etc, based on emerging safety , tolerability  and PK 
assessments .
There will be a washout interval of ≥5 day s between dosing to a given participant. 
Participants will be required to stay  at the CRU for the duration of the washout interval. 
However, they  may  be released at the discretion of the investigator. The washout interval 
may be adjusted based on data emerging from previous cohorts/periods.
PART -2:MAD
The first MAD cohort may start after asame total daily  dose ,which provides comparable or 
higher total daily  exposure (24 h) in SAD than the projected total dail y steady -state exposure
(over 24 h) at the starting dose in MAD, is found safe and well tolerated in PART- [ADDRESS_1145273] of approximately  2to 5 cohorts including up to 3 optional cohorts 
(Cohort 5, 6 and 7) with approximately  6 participants in each cohort. Cohort 7 is anoptional 
Japanese participants cohort .
PART -3: RBA and Food effect
If conducted, this cohort will be an open label, randomized, [ADDRESS_1145274] period. The washout interval may  be adjusted based on data emerging from SAD and 
MAD cohorts.
PART -4: Metabolism and Excretion
This part will include a single cohort of approximately  6male participants with at least 
4completers . All participant will receive [ADDRESS_1145275] 10h of fasting. The pa rticipants will be discharged on 
Day 11. 

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 15In PART-1 and 2, treatment sequences, actual doses, dose increments and dosing regimen 
may be adjusted, and intermediate or alternative dose levels may be substituted during the study based on emerging safety, tolerability, and PK data.
PART-5: Supratherapeutic Exposure (NH CRU only)
This cohort will include up to 12 participants in a 4-period (Periods 3 and 4 are optional), 
double-blind, sponsor-open, randomized, 2-sequence, cross-over design to explore safety, tolerability and PK at supratherpeutic exposure. For each period, participants will receive split dosing administration (3 doses) of PF-07321332 or placebo at short intervals (approximately 2 h of the previous dose) after at least [ADDRESS_1145276] 2 periods will be a cross-over where participants will be given PF-07321332 at 0, 2 and 4 hours at the dose of 750 mg (or placebo) with ritonavir. Periods 3 and 4 (if conducted) will only be conducted if supratherapeutic concentrations are not reached in Period 1. In periods 3 and 4 (if conducted) doses may be given up to 4 times for a total daily dose not exceeding 3000 mg, with or without food.
Number of ParticipantsA total of up to 78 participants (12 in PART-1: SAD, up to 30 [with 2 cohorts and 3 optional 
cohorts] in PART-2: MAD, a maximum of 18 in PART-3: Relative Bioavailability /Food 
Effect cohort,6 participants in PART-4: Metabolism and Excretion cohort and up to 12 participants in PART-5: Supratherapeutic Exposure) are planned to be randomized in this study. At the discretion of the sponsor and investigator, participant who were enrolled in PART-[ADDRESS_1145277]. Participants will be admitted to the CRU on Day -1 or earlier and may be discharged at investigator discretion following completion of assessments per SoA. 
PART-1: SAD
For each period, approximately [ADDRESS_1145278]. Each participant may receive either a single dose of PF-07321332 or a placebo during each period. In each period, participants on active treatment in Cohort 1 will receive D1, D3, D5 and D7(optional) dose levels ( Section 4.3 , Table 9 ) and Cohort 2 will receive D2, D4, D6 and D8
(optional) dose levels ( Section 4.3 ) in dose escalation format. In SAD cohorts requiring 
co-administration of PF-07321332/placebo with ritonavir, all participants (active and placebo) will receive 3 doses of 100 mg of ritonavir at -12h, 0h (coadministered with PF-07321332) and 12h.CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 16PART -2: MAD 
In each cohort, approximately  4participants will receive one of the escalating doses of
PF-[ADDRESS_1145279] for the next dose(s). From Day 1 –Day 9, 
PF-
07321332/placebo will be administered every  8h(ie,TID)when administere d alone and 
every  12h (ie,BID)when co -administered with ritonavir ; however, PF -07321332 /placebo
alone may  also be administered every  12h (ie,BID), if needed, based on emerging PK data. 
On Day 10, PF -07321332/placebo will be administered at approximately 0h for TID or BID 
regimen. In MAD cohorts requiring co -administration of PF -
07321332/placebo with 
ritonavir, all participants (active and placebo) will receive 100 mg of ritonavir as specified in 
the SoA .
PART -3: RBA and Food effect
The dose level to be evaluated in relative bioavailability /food effect cohort will be 
determined based on emerging PK and safet y data from SAD and MAD cohorts. The 
selected dose will be equal or lower than the highest tolerated dose already evaluated in 
SAD. There will be a washout interval of at least [ADDRESS_1145280] period. The 
washout interval may  be adjusted based on data emerg ing from SAD and MAD cohorts. 
PART -4: Metabolism and Excretion
This part will include a single cohort of approximately  [ADDRESS_1145281] 10h of fasting. The plasma for PK and metabolic 
profiling will be collected as specified in SoA. The urine and feces will be collected for 
10days as specified in SoA to determine excretion routes and metabolite profiling. Dietary  
fiber supplementation and use of laxative ( Section [IP_ADDRESS]) should be considered with the 
goal to facilitate at least once daily bowel movement. The participants will be discharged on 
Day 11. 
PART -
5: Supratherapeutic Exposure
In this part, f or each period, participants will receive split dosing (3 doses) of PF-07321332
or placebo at short intervals (within 2 h of the previous dose ).Participants will receive first 
split dose of PF-07321332 /placebo oral suspension at approximately  08:00 hours (±2 hours)
at least 2h after the morning breakfast per the So. The second and third split doses will be 
administered at approximately  2h and 4h after the first dose , respectivel y. 
A total of 3 doses of 100 mg ritonavir tablet wi ll be administered as a PK boosting agent as 
per SoA (approximately  [ADDRESS_1145282] split dose) .  

PF-[ADDRESS_1145283] may  be substituted with an on -site visit in case of additional follow- up of 
open A Es or clinicall y significant laboratory findings. 
The total planned duration of participation, from Screening visit to the Follow- up phone call, 
may be approximately  12 weeks for PART
-1and PART -5, 10 weeks for PART- 2 and 
PART -
3and 8weeks for PART -4.
Data Monitoring Committee or Other Independent Oversight Committee : No
Statistical Methods
The sample size for PART -1 and PART -
2 of the study  has been chosen based on the need to 
minimize exposure ofhealthy  participants toa new chemical entity  and the re quirements to 
provide adequate safet y and toleration 
and PK information at each dose level.
For PART- 3, the sample size will provide adequate precision to compare the relative 
bioavailability  of a tablet formulation of PF -07321332 relative to oral suspens ion.
For Part 4: A sample size of approximately  6male participants (with at least 4 completers) is 
chosen based on the industry  standard sample size for metabolism and excretion studies. This 
sample size was not justified by  [CONTACT_705108][INVESTIGATOR_825875].
For Part 5: A sample size of up to 12 participants (with at least 10 completers) is chosen 
based on the need to provide adequate safety , tolerability and PK information at each dose 
level and/or administration schedule.
The data from the 5parts of this study  will be analy zed and reported separately  in a single 
CSR.
All safet y anal yses will be performed on the safet y anal ysis set, which is defined as all 
participants randoml y assigned to stud y intervention and who receive at least one dose of 
study  intervention. Participants will be analy zed according to the product they  actuall y 
received. Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate . Plasma concentrations will be listed and summarized 
descriptively by[CONTACT_306917]. The plasma PK parameters will be 
summarized descriptively b y dose. No formal inferential statistics will be applied to the PK 
data apart from the comparisons of formulation an d food effect in either PART- 1 or PART - 3, 
if conducted.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 181.2.Schema
Figure 1
.C4671001 Study Design
*Optional dose levels in SAD/MAD may be used to explore higher doses or food effect or relative 
bioavailability or in combination with ritonavir (see more details in Section 4.1). Dosing with food may be done 
in one or more cohorts in SAD/MAD based on the emerging PK/ safety data. PART -4: Metabolism and 
Excretion (M&E) is an open -label single dose cohort (see more details in Section 4.1).PART -5:
supratherapeutic exposure (SE) is a double -blind, sponsor -open, randomized ,cross -over cohort (See more 
details in Section 4.1).
SAD dose levels D1 to D8 and MAD dosing regimens DR1 to DR4 are listed in Table 9and Table 10, 
respectively in Section 4.3.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 191.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in addition to those listed i n the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Table 1.PART -1: Single Ascending Dose Cohorts
Visit IdentifieraScreening Periods 1 -4bF/U
Contactc,jE/T
Days Relative to Day [ADDRESS_1145284] Dose 00.25 0.5 11.5 246812 1624h 48h 72h 96h 120h
Informed consent X
Inclusion/exclusion criteria X Xd
Dem ographics (including height & weight) X
Medical/Medicine history X Xd
SARS -CoV- 2 RT -PCReX XdXd
COVID -19 AssessmentrX X X X X X Xh
CRU ConfinementfX              X Xh
Physical examgX X X
Vital signs (temperature, respi[INVESTIGATOR_697], 
pulse rate, blood pressure)X X X X X X X X X X X
12-Lead ECG (triplicate) X X X X X X X X X X X
Continuous cardiac telemetry monitoringiX       X
Contraception check X XdXjX X
Serious and nonserious AE monitoring X                 X X
Study intervention administration
PF-07321332 or PlaceboqX
Ritonavir (if used) XkX X

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 20Table 1. PART-1: Single Ascending Dose Cohorts
Visit IdentifieraScreening Periods 1-4bF/U
Contactc,jE/T
Days Relative to Day [ADDRESS_1145285] D ose 00.25 0.5 11.5 246812 1624h 48h 72h 96h 120h
Blood Samples for:
Pregnancy test (WOCBP only) X XdXjX
Safety laboratory (4h fasting except 6h
sample)XX X X X X X
HIV, HBsAg, HBsAb,lHBcAb and 
HCVAb X
Serum FSH (post-menopausal females 
only) X
Plasma Pharmacokinetics (PF-07321332) X X X X X X X X X X X X X X X
19F-NMR measurements and metabolite 
profilingpXX X X X
Urine Samples for:
Drug screen testing XXd
Urinalysis X X X X X X X
19F-NMR Measurement and metabolic 
profilingn,pXX → →→→→→→→→ → XXXX X
Feces Collection for:
19F-NMR Measurement and metabolic 
profilingo,pXX → →→→→→→→→ → XXXX X
a.Visit Identifier: Day relative to start of study treatment (Day 1).
b.Period 1 to Period 4: Washout duration of at least 5 days between dosing. May be adjusted based on emerging data. Period 3 and 4 are optional.
c.F/U Contact: [CONTACT_31051]-up phone call may occur via telephone 28-[ADDRESS_1145286] in the final period.
d.Period 1 only. If participants are discharged and readmitted, follow all Period 1 activities except I/E criteria, medical history update  CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 21e.SARS-CoV-2 RT-PCR: Screening, admission (Day -1), 4 days following admission (Day 4), ad hoc test based on symptoms, and for ambulatory on-site 
visits.
f.CRU Confinement: Participants will be required to stay at CRU from Day -1 in Period 1 until completing Day 4 (72h) activities in the final period .
g.Physical Examination: Complete physical examination will be conducted at Screening or upon admission (Day -1) in Period 1. Brief physical examination  
may be performed at other times, as appropriate, for findings during previous examination or new/open AEs, at investigator’s di scretion.
h.COVID-19 assessment and PCRU confinement : Not done in the last period.
i.Continuous cardiac telemetry monitoring: Baseline telemetry to be recorded for at least [ADDRESS_1145287] Period only, unless discharged at the discretion of the investigator.
k.Ritonavir: To be administered approximately 12 hours before PF-07321332 administration on Day 1.
l.HBsAb: Can be done either automatically or only if HBcAb or HBsAg is positive, as per local practices.
 
n.Urine Sample Collection: “Blank” pre-dose urine sample to be collected within 24h prior to dosing and at each subsequent 24h interval until dosing in ne xt 
period or up to 120 h, whichever is earlier. Forced void into the collection container at the end of each collection period.
o.Feces Sample Collection: “Blank” fecal sample to be collected at baseline from at least one bowel movement during the 48h predose interval. Fecal 
samples will also be collected at intervals of 0-[ADDRESS_1145288] oral dose, and at each subsequent 24h interval until dosing in next p eriod or up to 120 h, whichever 
is earlier.
p.Metabolite profiling and quantitative F-NMR: conducted for Cohort 1, Period 2 only.
q.Study Drug Administration: The study drug should be administered after approximately at least 10h of fast in the morning dose (0h). For dosing in fed 
condition, please refer Section 5.3.1 .
r.COVID-19 Assessment: Temperature check as per local requirement. Questionnaire before admission.C
CI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 22Table 2. PART-2: Multiple Ascending Dose Cohorts (Including Optional Japanese Cohort)
Visit IdentifieraScreening F/U
Contact[CONTACT_825895] 1 Days
-28 to -2Day 
-1Day 
1kDay 2 Day 3 Day 4 Day 
5kDay 6 Day 7 Day 8 Day 9 Day 
10kDay 11 Day 
12Day 38-45
Informed consent X
Inclusion/exclusion criteria X X
Demographics (including height & weight) X
Medical/Medicine history X X
SARS-CoV-2 RT-PCRcXX X
COVID-19 AssessmentmX XXXXX X XXXXX XX
CRU ConfinementdX→→→→→→→→→→→ X
Physical exameXX X
Supi[INVESTIGATOR_825876] (temperature, respi[INVESTIGATOR_862], pulse rate, blood pressure)fXX X X X X X X
12-Lead ECG (triplicate)fXX X X X X X X
Contraception check X X X X X
Serious and nonserious AE monitoring X →→→→→→→→→→→→ XX X
Study intervention administration
PF-07321332 or Placebo (BID or TID)gXXXX X XXXXX
Ritonavir BID (if used)lXXXX X XXXXX
Blood samples for:
Pregnancy test (WOCBP only) X X X X
Safety laboratory (4h fasting)oXX X X X X X X X
TSH and Free T4 XqXqX
HIV, HBsAg, HBsAbn, HBcAb and HCVAb X
Serum FSH (post-menopausal females only) X
Plasma Pharmacokinetics (PF-07321332) X X j Xj XX j Xj XX j Xj X
Metabolite profiling X XCCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 23Table 2. PART-2: Multiple Ascending Dose Cohorts (Including Optional Japanese Cohort)
Visit IdentifieraScreening F/U
Contact[CONTACT_825895] 1 Days
-28 to -2Day 
-1Day 
1kDay 2 Day 3 Day 4 Day 
5kDay 6 Day 7 Day 8 Day 9 Day 
10kDay 11 Day 
12Day 38-45
Optional Microsampling Pharmacokinetics 
(PF-07321332)pXjXj
Urine samples for:
Drug screen testing X X
UrinalysisoXX X X X X X X X
Pharmacokinetics X X
a.Visit Identifier: Day relative to start of study treatment (Day  1).
b.F/U Contact: [CONTACT_31051]-up contact [CONTACT_693754] [ADDRESS_1145289].
c.SARS-CoV-2 RT-PCR: Screening, admission (Day -1), 4 days following admission (Day 4), ad hoc test based on symptoms, and for ambulatory on-site 
visits.
d.CRU Confinement: Participants will be required to stay at CRU from Day-1 until completing Day 12 activities.
e.Physical Examination: Complete physical examination will be conducted at Screening or upon admission (Day -1). Brief physical examination may be 
performed at other times, as appropriate, for findings during previous examination or new/open AEs, at investigator’s discretio n.
f.Vital signs and 12-lead ECG: Except on D1, D5 and D10, all vital signs and ECGs are to be collected pre-dose. on D12, collected 48h after last dose of 
PF-07321332/placebo.
g.Study drug administration: From Day 1 – Day 9 at approximately 0, 8 and 16 h for TID regimen (ie, every 8 h) of PF-07321332/placebo alone and at 
0 and 12h for BID regimen (ie, every 12h). On Day 10, at approximately 0h for TID or BID regimen of PF-07321332/placebo. The stud y drug should be 
administered after approximately at least 7h of fast in the morning dose (0h) and at least [ADDRESS_1145290] for afternoon and/or  evening doses. For dosing in fed 
condition, please refer Section 5.3.1 .
 
 
j.Plasma PK sample and optional microsampling PK sample collections: To be collected prior to morning dosing, except D11 and [ADDRESS_1145291] dose of PF-07321332/placebo, respectively.
k.Day 1; 5 and 10: Refer to Table 3 .C
CI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 24l.Ritonavir dosing: To be used w ith BID dosing of PF -07321332/placebo only. On Day 10 12h Ritonavir will be administered without PF -07321332/placebo.
m.COVID -19 Assessment: Temperature check as per local requirement. Questionnaire before admission.
n.HBsAb: Can be done either automatically or only if HBcAb or HBsAg is positive, as per local practices.
o.Safety labs and urinalysis: should be taken pre -dose only, except on Day 5 ( refer to Table 3 ).
p.Optional Microsam pling exploratory PK sample: To be collected only at NHCRU.
q.TSH and Free T4 : Must be collected at least once before dosing. PI m ay choose to either collect at screening or Day - 1 or both.  

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 25Table 3. PART-2: PK Days (Day 1, Day 5, Day 10) in MAD Cohorts
Visit IdentifieraTreatment Period on PK Days
Days Relative to Day [ADDRESS_1145292] 1stDose on that day 0b0.5 11.5 246812160b0.5 11.5 246812160b0.5 11.524681216
COVID-19 assessmentcXX X X X X
Supi[INVESTIGATOR_825876] (temperature, pulse rate, 
respi[INVESTIGATOR_697], blood pressure)XX X X X X X
12-Lead ECG (Triplicate) X X X X X X X
Study intervention administration
PF-07321332 or Placebo (TID dosing)dXX X X X X X
PF-07321332 or Placebo (BID dosing)dXX X X X
Ritonavir BID (if used)hXX X X X X
Blood samples for:
Safety laboratory (4h fasting except 6h sample on 
Day5)XX X
TSH and Free T4 X
Plasma Pharmacokinetics (PF-07321332) if TID 
dosing X XXXX XX X X XXXXXX X X XXX X X X X XX
Plasma Pharmacokinetics (PF-07321332) if BID 
dosingX XXXX XX X X X XXXXXX X X X XXX X X X X XX
Metabolite Profiling X X X X X X
Urine samples for:
Urinalysis X X X
Pharmacokinetics and metabolic profiling (TID 
dosing)XeX→→→ →→→ X
Pharmacokinetics and metabolic profiling (BID 
dosing)XeX→→→ →→→→X
a.Visit Identifier : Day relative to start of study treatment (Day  1).
b.Day 1-0H, Day 5-0H and Day 10-0H : Predose sample collection/procedure, except for study intervention administration.
c.COVID-19 assessment: Temperature check as per local requirement. Questionnaire before admission.CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 26d.PF-07321332 or placebo administration: Morning dose (0h) to be administered after at least 7h of fast. Afternoon dose (8h) and/or evening doses (12h or 
16h) require at least 2h fast before dosing. For dosing in the fed condition, please refer Section 5.3.1 .
e.Urine sample for PK and metabolic profiling: A single aliquot of blank urine to be collected before dosing.
 
 
h.Ritonavir dosing : To be used with BID dosing of PF-07321332/placebo only. On Day 10, 12h Ritonavir will be administered without 
PF-07321332/placebo.C
CI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 27Table 4. PART-3: Relative Bioavailability/Food Effect Cohort
Visit IdentifieraScreening Periods 1-3bF/U
Contact[CONTACT_825896]/T
Days Relative to Day [ADDRESS_1145293] D ose 0 0.5 11.5 [ZIP_CODE] 16 24h 48h
Informed consent X
Inclusion/exclusion criteria X X
Demographics (including height & weight) X
Medical/Medicine history X X
SARS-CoV-2 RT-PCReXX
COVID-19 AssessmentnXX X X X X
CRU ConfinementfX→ →→→→→→ → → → X
Physical examgXX X
Supi[INVESTIGATOR_825877](temperature, respi[INVESTIGATOR_697], 
pulse rate, blood pressure)XX X X
12-Lead ECG (single)hXX X X
Contraception check X X X X X
Serious and nonserious AE monitoring X →→ → → → → → → → →→ XXX
Study intervention administration
PF-07321332mX
Blood Samples for:
Pregnancy test (WOCBP only) X X X X
Safety laboratory ( 4h fasting) XX X X
HIV, HBsAg, HBsAb,jHBcAb and HCVAb X
Serum FSH (post-menopausal females only) X
Plasma Pharmacokinetics (PF-07321332) X X X X X X X X X X X X
Urine samples for:
Urine drug screen testing XX
Urinalysis X X X X
Other AssessmentsCCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 28a.Visit Identifier: Day relative to start of study treatment (Day  1).
b.Period 1 to Period 3: Washout duration of at least 2 days between dosing. May be adjusted based on emerging data.
c.F/U Contact: [CONTACT_31051]-up phone call may occur via telephone approximately [ADDRESS_1145294] in the f inal period.
e.SARS-CoV-2 RT-PCR: Screening, admission (Day -1), [ADDRESS_1145295] based on symptoms, and for ambulatory on-site 
visits.
f.CRU Confinement: Participants will be required to stay at CRU from Day-1 until completing Day 3 (48h) activities in the final period.
g.Physical Examination: Complete physical examination will be conducted at Screening or upon admission (Day -1) in Period 1. Brief physical examination 
may be performed at other times, as appropriate, for findings during previous examination or new/open AEs, at investigator’s di scretion.
h.12-lead ECG and Vitals: Single ECG. Based on emerging safety data, additional ECGs (including triplicate ECG) and/or vital measurements may be 
added.
i.Last Period only.
j.HBsAb: Can be done either automatically or only if HBcAb or HBsAg is positive, as per local practices.
 
m.Study Drug Administration: The study drug should be administered after approximately at least 10h of fast. For dosing in fed condition, please refer 
Section 5.3.1 . 
n.COVID-19 Assessment: Temperature check as per local requirement. Questionnaire before admission.C
C
IC
C
C
C
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 29Table 5. PART-4: Metabolism and Excretion Cohort
Visit IdentifieraScreening F/U
Contact[CONTACT_825897]/T
Days Relative to Day [ADDRESS_1145296] Dose 00.25 0.5 11.5 246812 1624h 48h 72h 96h-
216h240h
Informed consent X
Inclusion/exclusion criteria X X
Demographics (including height & weight) X
Medical/Medicine history X X
SARS-CoV-2 RT-PCRcXX X
COVID-19 AssessmentkXX X X X X X X
CRU Confinement Xl→→→→ → → → → →→→→→ XX X
Physical examdXX X
Vital signs (pulse rate, blood pressure) X X X X
12-Lead ECG (Single) X X X X
Contraception check X X X X X
Serious and nonserious AE monitoring X → →→→→ → → → → →→→→→→ → → XX
Study intervention administration
PF-07321332jX
Ritonavir XeXX X
Blood Samples for:
Safety laboratory (4h fasting) X X X X
TSH and Free T4 XmXmX
HIV, HBsAg, HBsAb,fHBcAb and 
HCVAb X
Plasma Pharmacokinetics (PF-07321332) X X X X X X X X X X XXXX X
Drug-related material measurement and 
metabolite profilingXX X X X X X
Urine Samples for:
Drug screen testing X XCCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 30Table 5. PART-4: Metabolism and Excretion Cohort
Visit IdentifieraScreening F/U
Contact[CONTACT_825897]/T
Days Relative to Day [ADDRESS_1145297] Dose 00.25 0.5 11.5 246812 1624h 48h 72h 96h-
216h240h
Urinalysis X X X X
Drug related material measurement and 
metabolic profilinghXX → →→→→→→→→ → XXX X X
Feces Collection for:
Drug related material measurement and 
metabolic profilingiXX → →→→→→→→→ → XXX X X
a.Visit Identifier: Day relative to start of study treatment (Day 1).
b.F/U Contact: [CONTACT_31051]-up phone call may occur via telephone 28-[ADDRESS_1145298].
c.SARS-CoV-2 RT-PCR: Screening, admission, [ADDRESS_1145299] based on symptoms.
d.Physical Examination: Complete physical examination will be conducted at Screening or upon admission (Day -1). Brief physical examination may be 
performed at other times, as appropriate, for findings during previous examination or new/open AEs, at investigator’s discretio n.
e.Ritonavir: To be administered approximately 12 hours before PF-07321332 administration on Day 1.
f.HBsAb: Can be done either automatically or only if HBcAb or HBsAg is positive, as per local practices.
 
h.Urine Sample Collection: A “Blank” pre-dose urine sample to be collected within 24h prior to dosing. Post-dose urine samples need to be collected at 
intervals of 0-24h post oral dose, and at each subsequent 24h intervals until discharge. Forced void into the collection contain er at the end of each collection 
period.
i.Feces Sample Collection: A “Blank” fecal sample to be collected at baseline from at least [ADDRESS_1145300] oral dose, and at each subsequent 24h interval until discharge.
j.Study Drug Administration: The study drug should be administered after approximately at least 10h of fast in the morning dose (0h). 
k.COVID-19 Assessment: Temperature check as per local requirement. Questionnaire before admission.
l.CRU Confinement: May be admitted earlier to facilitate pre-dose fecal collection. At the discretion of the investigator, one or more Day -1 assess ments 
may be conducted at admission if admitted earlier.
m.TSH and Free T4 : Must be collected at least once before dosing. PI [INVESTIGATOR_825878] -1 or both.C
C
I
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 31Table 6. PART -5: Supratherapeutic Exposure (NH CRU only)
Visit IdentifieraScreening Periods 1 -4bF/U
Contactc,iE/T
Days Relative to Day [ADDRESS_1145301] Dose [ZIP_CODE].5 44.5 55.5 6812 24h 48h 72h 96h
Informed consent X
Inclusion/exclusion criteria X Xd
Dem ographics (including height & 
weight)X
Medical/Medicine history X Xd
SARS -CoV- 2 RT -PCReX XdXd
COVID -19 AssessmentnX X X X X X X
CRU ConfinementfX              X X
Physical examgX XdX
Vital signs (temperature, respi[INVESTIGATOR_862], pulse rate, blood pressure)X X X X X X X X X X X X X X
12-Lead ECG (triplicate)rX X XXXXXXXXXX X X X X X
Continuous cardiac telemetry 
monitoringhX          X
Contraception check X XdXiX X
Serious and nonserious AE 
monitoring X                  X X
Standardized mealq X X X X X X X
Study intervention administration
PF-07321332 or PlacebomX X X
Ritonavir XjX X
Blood Samples for:
Pregnancy test (WOCBP only) X XdXiX
Safety laboratory (fasted for 4 h) X X X XiX
HIV, HBsAg, HBsAb ,kHBcAb a nd 
HCVAb X

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 32Table 6. PART-5: Supratherapeutic Exposure (NH CRU only)
Visit IdentifieraScreening Periods 1-4bF/U
Contactc,iE/T
Days Relative to Day [ADDRESS_1145302] D ose [ZIP_CODE].5 44.5 55.5 6812 24h 48h 72h 96h
Serum FSH (post-menopausal 
females onl y) X
Plasma Pharmacokinetics 
(PF-07321332) XpX X XXXXX XXXX X X X X X
TSH and free T4 XoXoXi
Urine Samples for:
Drug screen testing X Xd
Urinalysis X XdXXiX
a.Visit Identifier: Day relative to start of study treatment (Day 1).
b.Period 1 to Period 4: Washout duration of at least 5 days between 1stdosing in each period. Periods 3 and 4 are optional.
c.F/U Contact: [CONTACT_31051]-up phone call may occur via telephone [ADDRESS_1145303] in the final period.
d.Period 1 only. If participants are discharged and readmitted, follow all Period 1 activities except I/E criteria, medical history update  
e.SARS-CoV-2 RT-PCR: Screening, admission (Day -1), 4 days following admission (Day 4), ad hoc test based on symptoms, and for ambulatory on-site 
visits.
f.CRU Confinement: Participants will be required to stay at CRU from Day -1 in Period 1 until completing Day 5 (96h) activities in the final period.
g.Physical Examination: Complete physical examination will be conducted at Screening or upon admission (Day -1) in Period 1. Brief physical examination  
may be performed at other times, as appropriate, for findings during previous examination or new/open AEs, at investigator’s di scretion.
h.Continuous cardiac telemetry monitoring: Baseline telemetry to be recorded for at least [ADDRESS_1145304] Period only, unless discharged at the discretion of the investigator.
j.Ritonavir: To be administered approximately 12 hours before PF-07321332 administration on Day 1.
k.HBsAb: Can be done either automatically or only if HBcAb or HBsAg is positive, as per local practices.CCI
CCIC
C
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 33 
m.Study Drug Administration: The first split dosing of study drug should be at approximately 2h after the breakfast.
n.COVID-19 Assessment: Temperature check as per local requirement. Questionnaire before admission.
o.TSH and Free T4 : Must be collected at least once before dosing in each period. PI [INVESTIGATOR_825879] 1 Day -1 o r both.
p. Pre-dose sample.q.Standardized meal: On Day 1, the breakfast to be provided after collection of vitals, ECGs and approximately 2h before the administration 
of study intervention at 0h and lunch to be provided at approximately 4h after the last administration of PF-07321332/placebo.
r.ECG (triplicate): To be collected in fasted state (>3h after the previous meal).C
C
I
CCI
PF-[ADDRESS_1145305] in human (FIH) study of PF -07321332 in healthy  adult 
participants. It is a
5-part study  combining PART -1: SAD, PART -2: MAD ,PART -3: relative 
bioavailability /food effect, PART -4: metabolism and excretion and PART -5: 
supratherapeutic exposure (SE). PART -[ADDRESS_1145306] of an oral 
tablet formulation .PART -2 of the stud ymay also evaluate the safet y ,tolerability  and PK in 
Japanese participants . PART -4 is an open -label, non - randomized, single period to evaluate 
the metabolism and excretion of PF -07321332. PART -5 is a double -blind, sponsor -open, 
randomized, cross- over cohort to evaluate safet yand tolerability  at supratherapeutic 
exposures.
2.2.Backgrou nd 
Disease Overview
In December 2019, COVID -19 was identified as a new, potentially  fatal, respi[INVESTIGATOR_825880] b y the novel coronavirus, SARS -CoV -2. The WHO declared COVID - 19 a Public 
Health Emergency  of International Concern on 20 January 2020 and further characterized the 
disease outbreak as a pandemic on 11 March 2020.1
COVID -19 manifests as a wide range of illness
es, from as ymptomatic inf ection to severe 
pneumonia, ARDS and death. While the majority  of cases (approximately  80%) are 
asymptomatic or mild ,2patients who are hospi[INVESTIGATOR_21391] -[ADDRESS_1145307] significant 
morbidity  and mortality ,3,4and are at increased risk of developi[INVESTIGATOR_776748]- inflammatory  cytokines, ARDS, acute 
cardiac injury , thromboembolic events, hy percoagulability , and/or kidney  injur y.5-[ADDRESS_1145308] 
SARS -CoV -2, Remdesivir, an RNA poly merase inhibitor, has received approval in 
hospi[INVESTIGATOR_41374] -19.10
Antibody  cocktail s ( containing casirivimab and imdevimab ) and bamlanivimab received 
emergency  use authorization for recently  diagnosed patients with mild to moderate 
COVID -[ADDRESS_1145309] reduction of viral replication, through inhibition of other critical viral enzymes, offers an important mechanism as monotherapy or in combination, to achieve greater patient benefit.
Rationale for Development of PF-07321332The coronavirus 3CL protease is a virally encoded enzyme that is critical to the 
SARS-CoV-2 replication cycle, analogous to other obligatory virally encoded proteases (eg, HIV Protease, HCV Protease).
11Mutagenesis experiments with other coronaviruses and 
pi[INVESTIGATOR_295346]-CoV-2 (pi[INVESTIGATOR_295347]-like supercluster) have demonstrated that the activity of the 3CL protein (or the corresponding pi[INVESTIGATOR_295348] 3C enzyme) is essential for viral replication. No close human analogs of coronavirus3CL enzymes are known, suggesting that appropriate 3CL inhibitors may function as selective inhibitors of SARS-CoV-[ADDRESS_1145310] from that of 
Remdesivir, which is a prodrug of an adenosine nucleoside analogue that interferes with SARS-CoV-2 RNA-dependent RNA polymerase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Benefit/Risk Assessment
PF-07321332 is not expected to provide any clinical benefit to healthy participants. This 
study is designed primarily to generate safety, tolerability, and pharmacokinetic data for 
further clinical development.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PF-07321332 may be found in the IB, which is the SRSD for this study. The SRSD for the Ritonavir
19is the US FDA approved label and SmPC.CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER  
 
 
  
 
 
 
  
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
  
CCICCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 43 
 
   
 
 
    
 
   
 
  CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 442.3.2. Benefit Assessment
For healthy  participants in this study , no clinical benefit is expected. 
2.3.3. Overall Benefit /Risk Conclusion
PF-07321332 is not expected to provide an y clinical benefit to health y participants in this 
study . Taking into account the measures taken to minimize risk to participants of this study , 
the potential risks identified in association with adm inistration of PF -07321332 is clinically  
acceptable .
3.OBJECTIVES AND ENDPO INTS
PART -1: SAD
Objectives Endpoints
Prim ary: Prim ary: 
To assess the safety and tolerability 
following asingle dose of PF -07321332 
alone or in combination with a PK 
boosting agent (ritonavir) .Frequency, severity, and causal relationship of TEAEs 
and withdrawals due to TEAEs .
Frequency and magnitude of abnormal laboratory 
findings .
Changes from baseline in vital sign measurements and
12-lead ECG parameters .
Secondary: Second ary: 
To assess the plasma PK profile of 
PF-07321332 following single ascending 
doses of PF -07321332 alone or in 
combination with a PK boosting agent 
(ritonavir) .Plasma PK parameters of PF-07321332: 
Cmax, Tmax, AUC last, Cmax(dn), AUC last(dn).
If data permit, AUC inf, AUC inf(dn), t½, V z/F, and 
CL/F .
Tertiary/Exploratory: Tertiary/Exploratory: 
To explore metabolites in plasma, urine, 
and feces ,if data permit .Qualitative characterization of metabolites of 
PF‑07321332 in pooled plasma, urine, and feces ifdata 
permit.
Quantitative excretion of drug -related 
material using 19F-NMR spectroscopy , if 
data permit .Total excretion of drug -related material in urine and 
feces separately, and both routes combined, expressed 
as a percent of total dose administered , if data permit.
To determine the oral bioavailability of a 
tablet formulation of PF -07321332 
relative to suspension, if e valuated 
(Optional) .The ratio of AUC last, AUC infand C maxof tablet 
formulation and suspension .
To evaluate the effect of food (high fat 
meal) on the exposure of PF -07321332 
following a single oral dose of 
PF-07321332 tablet formulation, if 
evaluated (Optional) .The ratio of AUC last, AUC infand C maxunder fed 
condition and fasted condition .

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 45PART -2: MAD (including optional Japanese cohort)
Objectives Endpoints
Prim ary: Prim ary: 
To assess the safety and tolerability 
following multiple ascending doses of 
PF-07321332 alone or in combination 
with aPK boosting agent (ritonavir) .Frequency, severity, and causal relationship of TEAEs 
and withdrawals due to TEAEs .
Frequency and magnitude of abnormal laboratory 
findings .
Changes from baseline in vital s ign measurements and 
12-lead ECG parameters .
Secondary: Secondary: 
To assess the plasma PK profile of 
PF-07321332 on Day s1, 5 and 10 
following multiple ascending doses of 
PF-07321332 alone or in combination 
with aPK boosting agent (ritonavir ).Plasma PK parameters of PF -07321332: 
Cmax, Tmax, AUC tau (where tau=8 hours for TID 
dosing or 12 hours for BID dosing), C min, Cmax(dn), 
AUC tau(dn), Cav, Rac, Rac,Cmax ,PTR,CL/F and V z/F.
If data permit, t½.
To assess the urinary PK profile of 
PF-07321332 on Day 10 following 
multiple ascending doses of 
PF-07321332 alone or in combination 
with a PK boosting agent (ritonavir) .PF-07321332 urinary PK parameters: 
Aetauand Ae tau%, CL r.
Tertiary/Exploratory: Tertiary/Exploratory: 
To explore metabolites in plasma if data 
permit .Qualitative characterization of metabolites of 
PF‑07321332 in pooled plasma ifdata permit.
To explore PK by [CONTACT_825894](s) , if evaluated (Optional) .Concentration of PF -07321332 , if evaluated .
PART -3: Relative Bioavailability/Food Effect Cohort
Objectives Endpoints
Prim ary: Prim ary: 
To determine the oral bioavailability of a 
tablet formulation of PF -07321332 relative 
to suspension .The ratio of AUC last, AUC infand C maxof tablet 
formulation and suspension .
Secondary: Secondary: 
To evaluate the effect of food ( high-fat
high-calorie meal) on the exposure of 
PF-07321332 follow ing a single oral dose 
of PF -07321332 tablet formulation .The ratio of AUC last, AUC infand C maxof tablet 
formulation under fed condition and fasted condition .
To determine the pharmacokinetics of 
PF-07321332 follow ing oral 
administration of tablet and suspension of 
PF-07321332 .Plasma PK parameters of PF -07321332: T max,Cmax,
AUC last, Cmax(dn), AUC last(dn), if data permit AUC inf, 
AUC inf(dn), t ½, CL/F, V z/F.

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 46•To determine the safety and tolerability of 
PF-07321332 following oral 
administration of tablet and suspension of 
PF-07321332.•Frequency, severity, and causal relationship of TEAEs 
and withdrawals due to TEAEs.
•Frequency and magnitude of abnormal laboratory 
findings.
•Changes from baseline in vital sign measurements and 
12-lead ECG parameters.
  
 
  
PART-4: Metabolism and Excretion 
Objectives Endpoints
Primary: Primary: 
•To determine the extent of excretion of 
drug related material in urine and feces after a single oral administration ofPF-07321332 with PK boosting agent ritonavir.•Total recovery of drug related material in urine and 
feces separately, and both routes combined, expressed as a percent of total dose administered.
Secondary: Secondary: 
•To determine the pharmacokinetics of 
PF-07321332 following oral administration of PF-07321332 with PK boosting agent ritonavir.•Plasma PK parameters of PF-07321332: T
max,Cmax,
AUC last, if data permit AUC inf, t½, CL/F, V z/F.
•To determine the safety and tolerability of 
PF-07321332 after a single oral 
administration of PF -07321332 with PK 
boosting agent ritonavir.•Frequency, severity, and causal relationship of TEAEs 
and withdrawals due to TEAEs.
•Frequency and magnitude of abnormal laboratory 
findings.
•Changes from baseline in vital sign measurements and 
12-lead ECG parameters.
Tertiary/Exploratory: Tertiary/Exploratory: 
•To characterize the metabolic profile and 
identify circulating and excreted metabolites following administration of a single oral dose of PF-07321332 with PK boosting agent ritonavir, if possible.•Metabolic profiling/identification and determination 
of relative abundance of PF-07321332 and the metabolites of PF- 07321332 in plasma , urine, and 
feces, if possible.CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 47PART -5: Supratherapeutic Exposure (NH CRU only)
Objectives Endpoints
Prim ary: Prim ary: 
To assess the safety and tolerability of a 
supratherapeutic exposure of PF-07321332 
with a PK boosting agent (ritonavir)
administered as split dosing.Frequency, severity, and causal relationship of 
TEAEs and withdraw als due to TEAEs .
Frequency and magnitude of abnormal laboratory 
findings .
Changes from baseline in vital sign measurements 
and 12 -lead ECG parameters .
Second ary: Secondary: 
To assess the plasma PK of PF -07321332 at a 
supratherapeutic exposure of PF-07321332 
with a PK boosting agent (ritonavir)
administered as split dosing.Plasma PK parameters of PF -07321332: 
Cmax, Tmax, AUC last
If data permit, AUC inf, t½.
4.STUDY DESIGN
4.1.Overall Design
This study  may  be conducted at 1 -3 sites in the [LOCATION_003] and/or European U nion. 
This Phase [ADDRESS_1145311] -in-human (FIH) stud y will evaluate safety, tolerability, and PK of 
PF-07321332 in 
health yparticipants. This 5-part study  will combine PART -1: single 
ascending dose (SAD) , PART -
2:multiple ascending dose (MAD , including optional 
Japanese cohort ),PART -3: relative bioavailability and food effect cohort ,PART -4: 
metabolism and excretion cohort and PART -5: supratherapeutic exposure cohort . PART - 1 
and 2 are randomized, double -blind (participant and investigator blinded and sponsor open) 
and PART -[ADDRESS_1145312]. Participants will be admitted to the CRU on Day  -1 or earlier and may  be discharged 
at investigator discretion following completion of assessments per SoA.In PART -4, 
participants may  be admitted earlier to facilitate collection of pre- dose fecal sample. If a 
participant has an y clinically  significant, study related abnormalities at the conclusion of a 
scheduled inpatient portion of the study , the [COMPANY_007] medical monitor (or designated 
representative) should be notified and the participant may  be asked to remain in the CRU 
until such abnormalities are deemed not clinicall y significant, or it is safe for outpatient 
follow -up. 
Participants who discontinue for non -
safet y related reasons prior to completion of the study 
may be replaced, at the discretion of the PI [INVESTIGATOR_38107]. The replacement participant(s) may  
or may  not be required to complete all periods of the cohort in which they  are participating at 
the discretion of the PI [INVESTIGATOR_38107].

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 48Study  schema is shown in Section 1.2. In PART -1 and 2, t reatment sequences, actual doses, 
dose increments and dosing regimen may  be adjusted, and intermediate or alter native dose 
levels may  be substituted during the study  based on emerging safety , tolerability , and PK 
data.
PART -1: SAD
SAD will include 2 interleaving cohorts with a total of approximately  12 participants planned 
(approximately  6participants in each cohort), with 4-period cross -over in each cohort. 
Period [ADDRESS_1145313] (h
igh-fat high -calorie meal) , etc, based on emerging safety , tolerability  and PK 
assessments . For each period, approximately  4participants will receive a single oral dose of 
PF-07321332, and approximately  2participants will receive placebo after at least [ADDRESS_1145314] meal ( Section 5.3.1). If required to be 
dosed in fed state, the participants will be required to eat a meal before drug administration 
as specified in 
Sections 5.3.1 and 6.1.Each participant may  receive either a single dose of 
PF-
07321332 or a placebo during each per iod.In each period, participants on active 
treatment in Cohort 1 will receive D1, D3, D5 and D7 dose levels and Cohort 2 will receive 
D2, D4, D6 and D8 dose levels in dose escalation format as specified in Table 9
(Section 4.3). Provisional dosing scheme in PART - 1 is provided in Table 6. In  SAD cohorts 
requiring co
-administration of PF-07321332/placebo with ritonavir, all participants (active 
and placebo) will receive 3 doses of 100 mg of ritonavir as specified in the SoA. Except D1 
of Cohort 1 in SAD, all other dose levels and/or meal condition may  be changed b ased on 
emerging PK and safet y data. Dose escalation to subsequent dose levels in SAD cohorts will
be based on all available (a minimum of [ADDRESS_1145315]-dose) safety  data and PK over 
approximately  ≥6hours in a minimum of 4 participants (3active and 1 placebo) at previous 
dose levels.
Table 6. Provisional Dosing Scheme in Part -1:SAD
Period 1
Period 2 Period 3aPeriod 4a
Cohort 1 N=2 Placebo ( PL) D3 D5 D3 (Tablet)b
N=[ADDRESS_1145316]
N=[ADDRESS_1145317] D3 (Tablet)b
Cohort 2 N=[ADDRESS_1145318]+Food
N=[ADDRESS_1145319] D6 D2+Foodb
N=[ADDRESS_1145320] D2+Foodb
Dose levels D1 to D6 are specified in Table 9.
a.Period [ADDRESS_1145321] conducted in Period 3 or 4 , the 
active/Placebo allocation will be the same as equivalent dose used in period 1 or 2 .

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 49There will be a washout interval of ≥5 day s between dosing to a given participant. 
Participants will be required to stay  at the CRU for the duration of the washout interval . 
However, they  may  be released at the discretion of the investigator. The washout interval 
may be adjusted based on data emerging from previou s cohorts/periods. 
Optional Period [ADDRESS_1145322] (high
-fat 
high-calorie meal) and/or relative bioavailabilit y. If conducted, the active/Placebo allocation 
will be the same as equivalent dose used in Period 1 or 2.
Atdose level of D3 (Cohort -1, Period 2) , the urine and feces will be collected for 5 day sas 
specified in SoA for 19F-NMR spectroscop y and metabolite profiling. Based on the emerging 
PK data, the dose level for urine and feces c ollection may be changed. If needed, the feces 
and urine may  also be collected at an additional dose level. 
PART -2: MAD 
The first MAD cohort may start after atotal dail y dose, which provides comparable or higher
total daily  exposure (24h) in SAD to the projected total daily stead y-state exposure (over 
24h) at the starting dose in MAD, is found safe and well tolerated in the PART -[ADDRESS_1145323] of approxim ately 2to 5cohorts including up to 3 optional cohorts 
(Cohort 5, 6 and 7) with approximately  6 participants in each cohort. Cohort 7 is anoptional 
Japanese participants cohort. In each cohort, approximately  4participants will receive one of 
theescalat ing doses of PF - 07321332 as specified in Table 10(Section 4.3) and 
approximately  2participants will receive matching placebo after at least 
7h of fast for the 
morning dose and 2h of fast for the next dose(s) .From Day 1 –Day 9, PF -07321332 /placebo
will be administered every  8h(ie,TID)when administered alone and every  12h (ie,BID)
when co -administered with ritonavir ;however, PF -
07321332/placebo alone may  also be 
administered every  12h, if needed, based on emerging PK data. On Day 10, 
PF-07321332/placebo will be administered at approximately  0h for TID or BID regimen. In 
MAD cohorts requiring co
-administration of PF -07321332/placebo with ritonavir, all 
participants (active and placebo) will receive 100 mgof ritonavir as specified in the SoA .If 
required to be dosed in fed state, the participants will be required to eat a
meal before drug 
administration (as specified in Sections 5.3.1 and 6.1). Dose escalation to subsequent dose 
levels in MAD cohorts will be based on a minimum of 6 days safet y data and PK over 
approximately  ≥6hours on Day  5 in a minimum of 4 participants (3 active and 1 placebo) at 
previous dose levels. 
Safety , tolerability  and PKmay be evaluated in participants of Japanese descent ( defined as 
having 4 biological Japanese grandparents who were born in Japan ) after multiple oral 
administration of PF -[ADDRESS_1145324] dose level alread y evaluated in healthy  western participants .Frequency  of 
administration and meal condition will be based on safet y, tolerabilit y and PK data from 
MAD cohorts.

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 50If possible, microsampling PK and/or metabolite profiling may also be done.
PART-3: RBA and Food effect
If conducted, this cohort will be an open label, randomized, 3-period, 3-sequence cross-over 
single dose cohort evaluating the relative bioavailability of PF-[ADDRESS_1145325] of food on the bioavailability of the PF-07321332 tablet in healthy adult participants (Table 7).  
 
Number of participants required in this part of the study will be 
determined based on the variability observed in PK data emerging from SAD cohorts. A maximum of [ADDRESS_1145326] period. The washout interval may be adjusted based on data emerging from SAD and MAD cohorts. 
Table 7. Randomization Sequence in Relative Bioavailability/Food Effect Cohort
Sequence Period 1 Period 2 Period 3
1 A B C
2 B C A
3C A B
A: PF-07321332 oral suspensi on in fasted state.
B: PF-07321332 tablet formulation in fasted state.C: PF-07321332 tablet formulation in fed (high-fat high-calorie meal) state.
PART-4: Metabolism and Excretion
This part will include a single cohort of approximately [ADDRESS_1145327] 10 hr of fasting. The plasma for PK and metabolic profiling will be collected as specified in the SoA. The urine and feces will be collected for 10 days as specified in SoA to
determine excretion routes and metabolite profiling. A fecal sample is required prior to dosing on Day 1. Dietary fiber supplementation anduse of laxative ( Section [IP_ADDRESS] ) should 
be considered with the goal to facilitate at least once daily bowel movement. The use of the laxative should be recorded. The participants will be discharged on Day 11. 
PART-5: SE (NH CRU only)
This cohort will include up to 12 participants in a 4-period (Periods 3 and 4 are optional), 
double-blind, sponsor-open, 2-sequence, cross-ove r design to explore safety, tolerability and 
PK at supratherpeutic exposure. For each period, participants will receive split dosing CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 51administration (3 doses) of PF -07321332 or placebo at short intervals (approximately  2 h of 
the previous dose) after at least [ADDRESS_1145328] 2 periods will be a 
cross -over where participants will be given PF -07321332 at 0, 2 and 4 hrs at the dose of 
750mg(or placebo). 
Periods 3 and 4 (if conducted) will only  be conducted if 
supratherapeutic concentrations are not reached in Period 1. I n Periods 3 and 4 (if conducted) 
doses may  be given up to 4 ti mes for a total daily  dose not exceeding 3000 mg, with or 
without food. The timing of the food, ECGs, PK collection 
in Periods 3 and 4 may  be 
modified based on the data from Period 1 but the total number of these assessments will 
remain the same. 
In each period, participants will receive 3 doses of 100 mg ritonavir as specified in SoA.
Provisional dosing scheme in PART -5 is provided in Ta ble 8.
Table 8. Provisional Dosing Scheme in Part - 5:Supratherpeutic Exposure
Sequence Period 1 Period 2 Period 3aPeriod 4a
1 Placebo ( PL) Treatment P PL Treatment Q
[ADDRESS_1145329]
a.Period s3 and 4 are optional. 
Treatment P=750 mg of PF -07321332 to be administered at 0, 2 and 4h andPK enhancer (ritonavir)
administered at -12, 0 and 12h. Treatment Q = To be determined
There will be a washout interval of ≥5 day s between dosing of PF -07321332/placebo to a 
given participant. Participants will be required to stay  at the CRU for the duration of the 
washout interval. However, they  may  be released at the discretion of the investigator .
Dose escalation, if required, to subsequent dose levels (Treatment Q) in Period s
3 and 4 will 
be based on all available (a minimum of [ADDRESS_1145330]- dose) safety  data and PK data over 
approximately  ≥6hours (after the first dose on Day  1) in Period 1.
Thedose escalation stoppi[INVESTIGATOR_825881] 6.6.1. The total daily  dose in 
this part will not exceed 3000 mg .
In PART
-1 and PART -2 of the study , the dose levels, frequency  of administration and/or 
meal condition may  be changed based on emerging PK and safet y data. During the SAD and 
MAD the dose increments and planned doses may  be adjusted, as the study  progresses 
dependent upon emerging PK, safety, and tolerability  data. Other intermediate doses or lower 
doses may  be administered instead of the planned doses, or changes in dosing frequency  or 
titration schemes may  be proposed for MAD cohorts if safet y/tolerability  or PK issues 
become apparent, if evidence of nonlinear PK dictate s the need to escalate more slowly , or if 
subsequent doses are predicted to result in exposures that exceed the target limits. Any  
potential altered dose scheme will be equal to or less than a 3.[ADDRESS_1145331] dose if a higher dose is warranted to achieve exposure. If 
gastrointestinal tolerability  issue becomes dose -limiting in PART -1 or 2, dosing with food 
(standard meal) or pre -dosing with anti -emetics may  be considered. The projected average 
exposure of the altered dose scheme will not exceed the exposure limit specified in 
Section 6.1.1.

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 52In all cohorts (all parts of the study), participants can be released after completing activities 
specified in SoA. A telephone follow-up contact [CONTACT_705119] [ADDRESS_1145332] may be substituted with an on-site visit in case of additional follow-up of open AEs or clinically significant laboratory findings.
The total planned duration of participation, from Screening visit to the Follow-up phone call, 
may be approximately 12 weeks for PART- 1 and PART-5, 10 weeks for PART-2 and 
PART-3 and 8 weeks for PART-4.
Participants who discontinue from the study (due to non-safety reasons) may be replaced at 
the Sponsor’s discretion.
4.2. Scientific Rationale for Study Design
Given the current study is the first to dose PF-07321332 to healthy participants, an escalating 
single dose design with careful assessment and ongoing review of safety and PK data of PF-07321332 is planned. The 5-part combined SAD, MAD, RBA/FE, M&E and SE design was selected because it provides the opportunity to shorten the drug development timeline, without compromising the safety of the participants.
Male and female of 18-[ADDRESS_1145333] safety assessments, fibrinogen, PT and aPTT will also be 
monitored  
PART-1: SAD
The crossover design will permit both a within and between participant assessment of safety, 
tolerability, and PK. Furthermore, 2 interleaving cohorts will permit assessment of safety and PK over a wider dose range within a given participant compared to a sequential cohort design. To permit an unbiased assessment of safety, the administration of active versus placebo in each period will be double blinded to site staff (except those involved in preparation of doses) as well as the study participants. 
For a given participant, dosing will be separated by ≥5 days. This planned dosing interval is 
deemed sufficient to permit washout of previous treatment. Based on the projected PF-07321332 effective t
½of ~2 hours (see Section [IP_ADDRESS] ), almost complete PK washout is 
expected within 24 hours of dosing.
In SAD period, the urine and feces may be collected to calculate total excretion of 
drug-related material using 19F-NMR technique and understand metabolic profile as 
described in previous publications.15CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 53If a reasonable dose of PF-07321332 is not able to achieve desired concentrations in the 
efficacious range, ritonavir may be used as PK boosting agent. If required, 3 doses of 100 mg ritonavir at -12h, 0h (co-administered with PF-07321332) and 12h may be used as boosting agent to increase the exposure of PF-07321332 because the primary route of elimination of PF-07321332 is expected to be via CYP3A4 mediated metabolism. This dose of ritonavir is a subtherapeutic dose and provides maximum CYP3A4 inhibition. In SAD, participants will begin receiving ritonavir dose approximately 12 hours before the PF-07321332 dose to maximize the PK boosting potential of ritonavir. Although ritonavir is generally recommended to be dosed under fed condition for better gastrointestinal tolerability, lower dose of ritonavir (100 mg) is expected to provide acceptable gastrointestinal tolerability based on the fact that lopi[INVESTIGATOR_054]/ritonavir combination are recommended to be dosed with or without food.
PART-2: MAD
The safety and tolerability will be collected up to [ADDRESS_1145334] of 
PF-07321332 on relatively longer dosing; however, the dose escalation decision will be based on Day 5 PK. PBPK simulations (including time dependent induction and inhibition potential) showed that the PK concentration after [ADDRESS_1145335] the PK and safety data to initiate the study in COVID-19 patients. By [CONTACT_2006] 10, the PK of PF-07321332 is expected to achieve steady-state and therefore, the steady-state plasma and urine PK will be determined on Day 10.
Exploratory microsampling PK sample may be collected to evaluate the microsampling 
techniques which may be employed in future clinical trials. 
In order to understand the qualitative metabolic profile of PF-07321332 at steady-state, 
exploratory plasma samples may be collected on Day 10.  
PART-3: RBA and FE
This part of the study will evaluate bioavailability of a tablet formulation relative to the 
formulation used in PART-1 and/or PART-[ADDRESS_1145336] on the PK of a new formulation in healthy participants. 
Based on the projected half-life of 2h, the 48h washing interval should be sufficient to 
provide the concentration <5% of C
maxin the subsequent period.
 
 CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 54PART-4: Metabolism and Excretion
This part is an open-label, non-randomized, single period cohort to evaluate the metabolism 
and excretion of PF-07321332 in healthy male participants. Only males will be included in this study given the desire to enroll a homogeneous population due to the small sample size.
A single dose of PF-07321332 is considered appropriate as available data do not indicate 
PF-07321332 PK are time-dependent, and hence, single dose data are considered predictive of steady state.
The urine and feces samples collected will only be analyzed at the end of the study to 
determine the amount of drug related material excreted. Considering the half-life and variability in gastrointestinal transit time, feces and urine will be collected up to 10 days after dosing to allow near complete collection of the drug or drug related materials.
PART-5: Supratherapeutic exposure (NH CRU only)
This part is a double-blind, sponsor-open, randomized, 2-sequence, cross-over cohort to 
evaluate safety, tolerability and PK at supratherapeutic exposures. The dose currently being evaluated in Phase 2/3 studies is PF-07321332/ritonavir 300/[ADDRESS_1145337] of food on QTc ie, ≥4h before and after T
max, while avoiding very long 
fasting requirements for the participants.
Considering half-life and inter-individual variability in PART-1 of this study, a wash out of 
≥5 days was deemed sufficient. 
 CCICCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 554.3. Justification for Dose
4.3.1. Justification of Dose for PART-1, PART-2 and PART-3 (Original Protocol, 
28 January 2021)
The approach for dose selection for this study includes consideration of all relevant 
information obtained in non-clinical pharmacology and toxicity studies with PF-07321332. 
Similar to other antiviral therapi[INVESTIGATOR_014],  PF-[ADDRESS_1145338] relevant. Based on this antiviral data the target C
effwas defined  
 
The human PK of PF-07321332 after single and multiple dose administration (with and 
without ritonavir) was predicted using physiology based pharmacokinetic (PBPK) modeling by [CONTACT_825898] (HLM) and CL
bilefrom human hepatocytes under sandwich-cultured conditions in SimCyp®ADME 
simulator Version 19 release 1 (Certara, NJ, [LOCATION_003]). The predicted plasma CL and Vss of PF-07321332 are  and 1 L/kg, respectively, providing  
. In addition, inhibition (reversible and time dependent inhibition of 
CYP3A), induction potential and transporter interaction potential of PF-07321332 were also included in the PBPK model. For ritonavir, in-built PBPK model in SimCyp simulator was used. 
 
 
 
 
 
 
 
The planned starting dose of PF-07321332 as a single dose is 150 mg. Being an anti-viral 
agent, the target (3CL-protease) is not expressed in healthy participants hence primary pharmacology related effect is not expected in healthy participants. The projected average free concentration (C
average,free ) of approximately at 150 mg is more than 
1000 times lower than the observed IC 50(IC 50>100 μM) in off-target pharmacology 
screening panel. The projected total C maxand the AUC infof PF-07321332 at the proposed 
starting dose of 150 mg is  and , which provides approximatelyCCI
CCI
CCI
CCI CCI
CCI
CCI
CCI
CCI CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 56 safety margins (based on free concentrations), respectively. The maximum 
recommended starting dose based on human equivalent dose (HED) approach with safety factor of . Given the absence of target from healthy participants, absence of off-target pharmacology and high safety margin based on pre-clinical toxicology study, the 
proposed starting dose of 150 mg is expected to be safe.
Dose escalation is aimed to occur in incremental increases of ≤½ log (ie, up to approximately 
3.3-fold) based on predicted exposures. The margins for the highest proposed single dose (3000 mg) established on the free exposures in rats are projected to be approximately  for C
maxand  for AUC infwhich are well within the NOAEL exposure. In the presence 
of ritonavir, the projected exposure is lower than the projected exposures at the highest proposed dose of 3000 mg. 
The nominal doses, projected PK exposure parameters and safety margins of PF-07321332 
relative to PK stoppi[INVESTIGATOR_705088] 9. Doses presented are projected based on nonclinical data and may be modified based on emerging safety, tolerability, and PK data. The projected exposures (adjusted based on observed PK) at the modified doses will not exceed the PK stoppi[INVESTIGATOR_705089] ( Section 6.6.1 ). 
 
   
 
 
 
 
 
 
The starting dose in MAD cohort is planned at 500 mg TID; however, the starting dose in 
MAD may be adjusted based on available PK and safety data from the SAD cohorts. Based on the current human PK predictions, a dose of approximately 500 mg TID would provide the C
minconsistently above C eff. Since the target is not expressed in healthy participants, a 
dose that is expected to be efficacious is proposed as a starting dose in MAD in order to minimize the exposure of healthy participants at subtherapeutic dose levels. CCI
CCI
CCI
CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 57Based on the predicted steady state exposures (C max,ss and AUC 24,ss), 500 mg TID is expected 
to provide margins of approximately  for C max,ss and for AUC 24,ssrelative to the 
free exposure in rats on Day 14 at the NOAEL. All dose levels listed are nominal since doses will be driven by [CONTACT_80063]. Dose escalation is aimed to occur in incremental increases of≤½ log (ie, up to approximately 3.3-fold) based on predicted exposures.
Due to the uncertainties in the in vitro potencies and PK parameters scaling and anticipated 
interpatient variability, the current intent of the development program is to explore dosing regimens resulting in a multiple of this C
mintarget. Highest daily dose of PF-07321332 is 
expected to be 3000 mg/day (ie, 1000 mg TID), which is expected to provide margins of approximately for C
max,ss and  for AUC 24,ssrelative to the free exposure in rats
on Day 14 at the NOAEL.
The nominal dosing regimen, projected PK exposure parameters and safety margins of 
PF-07321332 relative to PK stoppi[INVESTIGATOR_825882] 10.
 
  
 
 
 
All the doses in SAD or MAD cohorts except starting dose of 150 mg in SAD cohort are nominal and may be adjusted, as the study progresses depending upon emerging PK, PD, safety, and tolerability data. Other intermediate doses or lower doses or repeat doses may be 
administered instead of the planned doses, or changes in dosing frequency or titration 
schemes may be proposed for MAD cohorts if safety/tolerability issues become apparent, if evidence of nonlinear PK dictates the need to escalate more slowly, or if subsequent doses are predicted to result in exposures that exceed the target limits. However, the projected exposure for the modified doses or additional cohorts following either single dose or multiple dose administration will not exceed PK stoppi[INVESTIGATOR_227505].CCI CCI
CCI CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 58The dosing regimen to be evaluated in optional Japanese cohort will be equal to or lower than 
the safe and tolerated dosing regimen in western healthy adult participants in MAD cohorts. Similarly, the dose to be evaluated in relative bioavailability cohort will be the dose which will be projected to provide the exposure (in fed condition) equal to or lower than the exposure already observed in SAD or MAD cohorts at safe and tolerated doses.
4.3.2. Justification of Dose for PART-4:Metabolism and Excretion (Protocol 
Amendment 2, 2 June 2021)
In PART-4: Metabolism and Excretion cohort, a single oral dose of 300 mg PF-07321332, 
pharmacokinetically enhanced with ritonavir (4 doses of 100 mg at -12, 0, 12, and 24 hours relative to PF-07321332), is planned. This dose is anticipated to be a clinically effective dose and currently planned to be evaluated in Phase 2/3 studies. 
 
 
 
 
 
 
The dose of ritonavir to be used in this study is 100 mg. This dose is the typi[INVESTIGATOR_825883] a PK enhancer. 
 
 
4.3.3. Justification of Dose for PART-5: Supratherapeutic Exposure (Protocol 
Amendment 3, 24 June 2021)
In PART-5, the total dose planned for PF-07321332 is 2250 mg administered as 3 split doses
of 750 mg at 0, 2h and 4h, pharmacokinetically enhanced with ritonavir (3 doses of 100 mg at -12, 0 and 12 hours relative to PF-07321332). Based on the simulations using preliminary population PK model, this dose is anticipated to provide a supratherapeutic exposure  
. 
 
 
 
 
 CCI
CCI
CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 59The dose of ritonavir to be used in this study is 100 mg. This dose is the typi[INVESTIGATOR_825884] a PK enhancer. 
The projected exposure for the proposed dose / regimen of PF-07321332 was based on a 
preliminary population PK model. The model for PF-07321332 750 mg (administered at 0h, 2h and 4h) with PK enhancement predicts the total AUC
24and C maxto be μg•hr/mL 
and μg/mL, which is less than  higher than the observed exposure at PF-07321332 
750 mg (with ritonavir), and approximately  and  lower, respectively, in terms of unbound concentration than the observed NOAEL  
 in rats in the 14-day toxicity study.
Using the same preliminary population PK model, the projected AUC
24and C maxat the 
maximum allowed dose in this protocol (3000 mg total daily dose administered as 4 split doses of 750 mg at every 2 hour intervals) are approximately μg•hr/mL and 
, which is approximately  and  below the PK stoppi[INVESTIGATOR_227505].
At this dosing regimen, the supratherapeutic exposure is expected to be achieved while being 
safe. 
4.4. End of Study Definition
A participant is considered to have completed the study if he/she has completed all phases of 
the study, including the last visit.
The end of the study is defined as the date of the last visit of the last participant in the trial 
globally.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
1. Male and female participants must be 18 to 60 years of age, inclusive, at the time of 
signing the ICD. Only Male participants will be included in PART-4.CCICCI
CCI
CCI CCI
CCI
CCI
CCI CCI CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 60Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.
Participants who are overtly  health y as determined by [CONTACT_227546] , phy sical examination, laboratory  tests, and vital signs and standard 
12-lead ECGs .
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests
, lifesty le considerations, and other study  procedures.
4.For optional Japanese cohort only: Japanese participants who have 4Japanese 
biologic grandparents who were born in Japan .
Weight: 
5.BMI of 17.5 to 30.5 kg/m2; and a total body  weight >50 kg (110 lb).
Informed Consent:
6. Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand i n 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy chiatric, neurological, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing).
2.Any condition possibly  affecting drug absorption (eg, gastrectomy , cholecy stectom y, 
intestinal resection ).  
3.Positive test result for SARS -CoV -2 infection at the time of screening or Day -1.
4.History  of HIV infection, hepatitis B, or hepatitis C; positive testing at screening for 
HIV, HBsAg, HBcAb , or HCVAb. As an exception a positive HBsAb test due to 
Hepatitis B vaccination is allowed.
5.Other medical or psy chiatric condition including recent (within the past y
ear) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk 
of study  participation or, in the inve stigator’s judgment, make the participant 
inappropriate for the study .

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 61Prior/Concomitant Therapy:
6.Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . (Refer to Section 6.5 for additional details ) .
7.Participants who have received a COVID -19 vaccine within 7 day s before screening 
or admission, or who are to be vaccinated with a COVID- 19 vaccine at any  time 
during t he stud y confinement period
Prior/Concurrent Clinical Study Experience:
8.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_1145339] dose of study  intervention
used in this study  (whichever is longer). 
Diagnostic Assessments:
9.A positive urine drug test at screening or admission .
10.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least [ADDRESS_1145340]. If BP is ≥140 mmHg (s ystolic) or ≥ 90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant ’s eligibility .
11.Baseline 12-lead ECG thatdemonstrates clinically relevant abnormalities thatmay
affect participant safety or interpretation of study results (eg, baseline QTc Finterval
>[ADDRESS_1145341]- degree AVblock, or serious brady arrhy thmias or tachy arrhy thmias). If the 
baseline uncorrected QT interval is >450 msec, this interval should be rate -corrected 
using the Fridericia method and the resulting QTcF should be used for decision 
making and reporting.   Computer -interpreted ECGs should be overread by a 
physician experienced in reading ECGs before excluding participant s
.In PART s-1,
2and 5 , the average of triplicate measurement should be used for eligibility 
determination. 
In PART -
3 and PART - 4 only : IfQTcFexceeds 450 msec , or QRS exceeds 
120msec, the ECG should be repeated 2 more times and the average of the 3 QTcFor 
QRS values should be used to determine the participant’s eligibility .  

PF-[ADDRESS_1145342], if deemed necessary: 
•AST orALT level ≥1.5 × ULN;
•Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's 
syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ULN.
Other Exclusions:
13. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spi[INVESTIGATOR_107060] 3 ounces (90 mL) of wine).
14. Blood donation (excluding plasma donations) of approximately 1 pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_1145343] of the 
study, site staff otherwise supervised by [CONTACT_093], and their respective family members.
18. Pregnant or breastfeeding women.
5.3. Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
•Participants must abstain from all food and drink (except water) at least 4 hours prior 
to safety laboratory evaluations (except 6h post dose on Day 1 in PART-1 and Day 5 in PART-2) and at least [ADDRESS_1145344] 7 hours before morning doses in PART-2.
•PART-5: On Day 1, the breakfast to be provided after collection of vitals, ECGs  
 and approximately 2h before the administration of study intervention at 0h 
and lunch to be provided at approximately 4h after the last administration of PF-07321332/placebo.
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 63•PART-1, PART-3, PART-4 and on PK days in PART-2 ( if dosed under fasted 
condition ):
•Water is permitted until 1 hour prior to study intervention administration at 0h on 
PK days. Water may be consumed without restriction beginning 1 hour afterdosing at 0h on PK days. Water consumption is not restricted on afternoon and/or evening dose(s) on PK days and on all doses of non-PK days.
•No food will be allowed for approximately [ADDRESS_1145345]-dose in PART-1, 
PART-3 and after the morning dose on PK days (Days 1, 5, 10) in PART-2. For all other doses in PART-2, no food will be allowed approximately 2 hours before and after dosing. 
•Noncaffeinated drinks (except grapefruit or grapefruit-related citrus fruit juices (see 
below) may be consumed with meals and the evening snack.
•Lunch will be provided approximately 4 hours after morning dosing.
•Dinner will be provided approximately 9 to 10 hours after morning dosing.
•An evening snack may be permitted.
•Participants will refrain from consuming red wine, grapefruit, or grapefruit-related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_1145346] dose of study intervention until collection of the final PK blood sample.  
•While participants are confined, their total daily nutritional composition should be 
approximately 55% carbohydrate, 30% fat, and 15% protein. The daily caloric intake per participant should not exceed approximately 3200 kcal.
PART-5 only:
•On Day [ADDRESS_1145347] meal. If participants are unable to complete the entire meal, the approximate portion of the meal consumed will be documented.
•Water is restricted for 30 minutes prior and 1 hour after dosing (1
st, 2ndand 3rdsplit 
dose). Ambient temperature water may be consumed without restriction 1 hour after 3
rdsplit dose.CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 64Participants will be restricted to consuming ambient temperature or warm drinks form 
Day 1 (prior to baseline ECG measurements) until final ECG measurements have 
been collected in each study  period. Hot or cold drinks are prohibited during this time 
frame.
Non-caffeinated drinks (except grapefruit or grapefruit- related citrus fruit juices) may  
be consumed with meals and evening snacks.
Participants will not be allowed to eat or drink grapefruit or grapefruit- related citrus 
fruits (eg, Seville oranges, pomelos) from [ADDRESS_1145348] period.
On Day  [ADDRESS_1145349] 
dosing (ie, following the scheduled 8hour ECG and PK assessments).
On Day  1 in all Periods, dinner will be provided approximately  8hours after lastsplit
dosing (ie, after collection of the ECG and PK measurements scheduled at12 hours 
postdose).
The timing of meals should be standardized between period [ADDRESS_1145350] fails to consume the majority  of a meal.
While participants are confined, their total daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  [ADDRESS_1145351] meal condition in PART -
1or PART -3:
Following an overnight fast of at least [ADDRESS_1145352] -dose.
Water can be allowed as desired except for [ADDRESS_1145353] 
administration. There are no water restri
ctions prior to dosing for participants dosed 
under fed conditions. 
If dosedunder high fat meal condition in PART -1 or PART -3:
Following an overnight fast of at least 10 h ours, participants should start a 
high-
fat/high- calorie breakfast approximately  30minutes prior to administration of 
the investigational product. The breakfast will be consumed over approximately 

PF-[ADDRESS_1145354] -dose.
The breakfast will be a high -calorie/high -fat test meal . The test meal should 
derive approximately  150, [ADDRESS_1145355] as a representative example of a 
high-fat, high -calorie meal : [ADDRESS_1145356] with butter , 4 ounces of hash brown potatoes, 8 fluid ounces (240 mL) of 
whole milk .
Water can be allowed as desired except for [ADDRESS_1145357] meal condition in PART-2:
Morning dosing condition:
Following an overnight fast of at least [ADDRESS_1145358] on PK profile assessment day s (Day s 1, 5 and 10) , the approximate portion 
of the breakfast consumed will be documented. On non -PK day s, it is not required to 
document the approximate portion of food consumed. No food will be allowed for at least 
2hours post -dose.
Water can be allowed as desired except for [ADDRESS_1145359] 
administration on PK days. There are no water restrictions on non -PK days neither 
prior to 
dosing for participants dosed under fed conditions.
Afternoon and/or evening dosing condition:
Asnack consisting of at least 400 kcal will be provided approximately  20 min utesbefore 
dosing in the afternoon and/or evening . The snacks will be consumed over approximately  
10minutes with investigational product administered within approximately 10 minutes after 
completion of the snack. Participants will be encouraged to eat the full snack .There is no 
food restrictions on afternoon and/or evening dos e(s).
There are no w ater restrictions on afternoon and/or evening dose(s) on PK day s and on 
non-PK day s.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Dietary Fiber Supplementation (PART -4 and PART - 5 only)
To help assure regularit y in bowel movements, nutritional composition should include high
fiber content. This may  include consumption of fiber capsules, at a frequency  dictated by
[CONTACT_1697], starting with the evening meal (ie, approximately  [ADDRESS_1145360] dose) on 
Day 1,for duration of inpatient stay  to ensure at least 
1bowel movement per day .
If an individual participant has not experienced a bowel movement in the first 24 hours after
dosing water intake should be increased and prune juice should be offered on Day 2.
Despi[INVESTIGATOR_37104], if bowel movement does not occur regularl y(ie,at least once dail y 
bowel movement) , consideration should be given to administration of mild laxative/stool 
softener (eg, milk of magnesia or docusate), at i
nvestigator’s discretion.
5.3.2. Caffeine, Alcohol, and Tobacco
Participants will abstain from caffeine containing products for 24 hours prior to the 
start of dosing of PF -07321332 /placebo until collection of the final PK sample of 
each stud y period. 
Participants will abstain from alcohol for 24 hours prior (or as specified above for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK sample of each study  period. Participants may  undergo an alcohol 
breath test or blood alcohol test at the discretion of the investigator.
Participants will abstain from the use of tobacco or nicotine containing products for 
24hours prior to dosing of PF -07321332/placebo and during confinement in the 
CRU. 
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) f or at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted
.
In order to standardize the conditions on PKsampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP , pulse rate , 
respi[INVESTIGATOR_825885]) for first 4 hours after morning dose
, and 
may be require d to follow meals and dietary  restrictions as specified in Section 5.3.1.
PART -
1and PART -5 only: Participants will be confined to the procedure room for 
the first [ADDRESS_1145361] PF-07321332/placebo dosing on Day 1during continuous 
cardiac monitoring, except to use the bathroom. After this, if the equipment setup 
allows, participants may  be ambulatory  during the ECG monitoring period, but 
should not engage in strenuous activities. If equipment does not allow ambulation, 
appropriate accommodations will be made by [CONTACT_825899] ( eg, bedside urinals should be provided to accommodate 
participants’ excretory  needs). 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 675.3.4. Contraception 
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s )from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 )and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant ’s affirmation in the 
participant ’s 
chart ( participant s need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception). In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contracept ion method is discontinued or if 
pregnancy  is known or suspected in the 
participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study intervention/enrolled in the study . Screen 
failure data are collected and remain as source and are not reported to the clinical database.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened. 
6.
STUDY I NTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to all of the following:
PF-07321332;
Placebo for PF -07321332 ;
Ritonavir .
6.1.Study Intervention(s) Administered
PF-
07321332 and placebo will be provided by  [CONTACT_825900] s 
preparation of oral suspensions at the CRU. 
PF-07321332 or placebo will be presented to the participants in indiv idual dosing containers.
In addition, PF -07321332 and matching placebo may  also be supplied as tablets. If provided, 
tablets will be 
supplied to the CRU in bulk along with individual dosing containers for unit 
dosing.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 68Ritonavir 100 mg tablets will be supplied locally  by [CONTACT_47365].
6.1.1. Administration
Dosing of PF -
07321332/placebo (placebo for PART -1 only ) and ritonavir (if used) in 
PART -1 and PART -3
If dosed under fasted condition, participants will receive PF- 07321332/placebo (placebo for 
PART -1 only )at approximately  08:00 hours ( ± 2 hours) per the SoA following an overnight 
fast of at least 10h. In PART -1, if required, 3 doses of 100 mg ritonavir may  be administered 
as a PK boosting agent as per SoA. At a time point w hen PF- 07321332 /placebo (placebo for 
PART -1 only ) will be dosed with ritonavir (ie,at 0h) , both PF - 07321332/placebo (placebo 
for PART -1 only ) and ritonavir will be dose dsimultaneously  (within no more than 5 minutes 
of each other) . Participants will swallow ritonavir and PF - 07321332/placebo (placebo for 
PART -1 only ) tablets whole (if administered as tablet) and will not chew prior t
o 
swallowing. 
Investigator site personnel will administer with ambient temperature water to a total volume 
of approximately  [ADDRESS_1145362].
If dosed under fed condition ( standard meal or high -fat high- calorie meal ), the 
PF-07321332/placebo (placebo for PART - 1 onl y)should be administered approximately  
10minutes after finishing the meal/snack (refer Section 5.3.1 for further details).
Dosing of PF -07321332/placebo and ritonavir (if used) in PART -2 
If dosed under fasted condition, participants will receive PF -07321332/placebo at 
approximately  08:00 hours (plus or minus 2 hours) per the SoA following an overnight fast 
of at least [ADDRESS_1145363] is required for afternoon and/or evening dosing for BID 
and TID dosing regimen. When dosed with ritonavir, both PF -07321332/p lacebo and 
ritonavir will be dose dsimultaneously  (within no more than 5 minutes of each other). 
Participants will swallow ritonavir and PF -07321332 /placebo tablets whole (if administered 
as tablet) and will not chew prior to swallowing.
Investigator site personnel
will administer with ambient temperature water to a total volume 
of approximately  [ADDRESS_1145364].
If dosed under fed condition (meal/snack), the PF-07321332/placebo should be administered 
approximately  10 minutes after finishing the meal/snack (refer Section 5.3.1 for further 
details).
Dosing of PF -
07321332 and ritonavi r in PART -4
Participants will receive PF -07321332 and ritonavir at approximately  08:00 hours ( ±2hours) 
per the SoA following an overnight fast of at least 10h. Participants will receive 4 doses of 
100 mg ritonavir as a PK boosting agent as per SoA. At a time point w hen PF -07321332 will 
be dosed with ritonavir (ie, at 0h) , both PF -07321332 and ritonavir will be dose d

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 69simultaneously  (within no more than 5 minutes of each other) in fasted state . Except when 
dosed with PF -07321332, ritonavir may  be administered with or without food. 
Participants 
will swallow ritonavir tablets whole and will not chew prior to swallowing. 
Investigator site personnel will administer PF-[ADDRESS_1145365]. 
Dosing of PF -07321332/placebo and ritonavir in PART - 5
In this part, for each period, particip ants will receive split administrations (3 doses) of 
PF-07321332 or placebo at short intervals (within 2 h of the previous dose ).
Participants will receive first split dose of PF-07321332 /placebo oral suspension at 
approximately  08:00 hours ( ±2hours) at least 2h after the morning breakfast per the SoA .
The second and third split doses will be administered at approximately  2h and 4h after the 
first dose , respectivel y
. A total of 3 doses of 100 mg ritonavir tablet willbe administered as a 
PK boosting agent as per SoA. At a time point w hen PF-07321332/placebo will be dosed 
with ritonavir (ie, at 0h) , both PF -
07321332/placebo and ritonavir will be dose d
simultaneously  (within no more than 5 minutes of each other). Participants will swallow 
ritonavir tablets whole and will not chew prior to swallowing. 
Investigator site personnel will administer with ambient temperature water to a total volume 
of approximately  240 mL. 
PF-07321332/placebo will be adm inistered according to the EDR. 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 70Intervention Name [INVESTIGATOR_16335]-07321332 Placebo Ritonavir (if used)
ARM Nam e
(group of patients 
receiving a specific 
treatm ent (or no 
treatm ent)PF-07321332 Placebo NA
Type Drug Placebo Boosting agent
Dose Form ulation Suspension or Tablet Suspension or Tablet Tablet
Unit Dose Strength(s) Planned nominal unit 
doses strength for 
tablets: 25 mg, 100 mg, 
and 250 mg0 mg 100 mg
Dosage Level(s) Planned nominal unit
doses strength for 
tablets: 25 mg, 100 mg, 
and 250 mg0 mg 100 mg
Route of 
AdministrationOral Oral Oral
Use Experimental Placebo PK Boosting agent
IMP or NIMP IMP IMP NIMP
Sourcing Provided centrally by 
[CONTACT_825901], subsidiary, or 
designee
Packaging and Labeling Materials (API [INVESTIGATOR_825886]) for 
extemporaneous prep of 
oral suspensions will be 
provided in bulk.
Tablets w ill be provided 
in bulk. PCRU staff will 
prepare individual doses 
for administration. 
Individual dose 
containers will be 
labeled by [CONTACT_825902].
Tablets w ill be provided 
in bulk. PCRU staff will 
prepare individual doses 
for administration. 
Individual dose 
containers will be 
labeled by [CONTACT_825903]/Former 
Nam e(s) or Alias(es)PF-07321332 Placebo Norvir®or other local 
commercialized product
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  interventions received and any  
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants e nrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) ar ea in accordance with the labeled storage 

PF-[ADDRESS_1145366] for storage conditions of the study  intervention once prepared .
7.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records), such as th e 
IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a study intervention accountabilit y form/record.
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the PCRU’s site procedures. All destruction must be 
adequatel y documented. If destruction is authorized to take place at the investigator 
site, the investigator must ensure that the materials are destro yed in compliance with 
applicable environmental regulations, ins titutional policy , and any  special instructions 
provided b y [COMPANY_007].
Upon identification of a product complaint, notify the sponsor within 1 business day  of 
discovery .
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by  [CONTACT_216479]. Dispensing is defined as the provision of study intervention, concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protocol. L ocal health authority  regulations or investigator 
site guidelines may  use alternative terms for these activities.

PF-[ADDRESS_1145367]. Prepared doses will be provided in unit dose containers and labeled in 
accordance with [COMPANY_007] regulations and the investigator site’s labeling requirements.
PF-07321332 and placebo tablets, if used, will be dispensed at the CRU in the individual 
dosing containers b y 2 operators, 1 of whom is an appropriatel y qualified and experienced 
member 
of the stud y staff (eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, 
pharmacy  assistant/technician, or pharmacist). The tablets will be provided in unit dose 
containers and labeled in accordance with [COMPANY_007] regulations and the clinical site ’s labeling 
requirements.
Ritonavir will be administered to the participant in an unblinded (open -label) fashion. 
Ritonavir tablets will be dispensed at the CRU in the individual dosing containers by  
2operators, 1 of whom is an appropriatel y qualified and experienced member of the stud y 
staff (eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, pharmacy  
assistant/technician, or pharmacist). The tablets will be provided in unit dose containers and 
labeled in accordance with [COMPANY_007] regulations a nd the clinical site’s labeling requirements.
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator will assign participant numbers to the participants as they  are screened for 
the study . [COMPANY_007] will provid e a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will receive the stud y treatment regimen 
assigned to the corresponding randomization number.
Investigators and participants will remain blinded to each participant’s assigned study  
intervention throughout the course of the stud y. In order to maintain this blind, an otherwise 
uninvolved third party  (for example, pharmacist) will be responsible for the preparation and 
dispensing of all study  intervention according to the randomization schedule and assigned 
treatment for the individual participant.
This third party  will instruct the participant to avoid discussing the taste, or packaging of the 
study  intervention with the investiga tor.
Blinding procedures do not apply  to PART -3and PART -4of this study  because it will be 
conducted as open -label. Where the design is open- label, the investigator’s knowledge of the 
treatment should not influence the decision to enroll a particular part icipant or affect the 
order in which participants are enrolled.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 736.3.2. Breaking the Blind 
The method for breaking the blind in this study  will be manual. In case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a par ticipant’s 
treatment assignment is warranted. Participant safety must alway s be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every  effort to contact [CONTACT_825904] a 
participant’s treatment assignment unless this could delay  further management of the 
participant. If a participant’s treatment assignment is unblinded, the sponsor must be notified 
within [ADDRESS_1145368] 
be fully  documented in a CRF .
Blood specimens will be obtained from all participants for PK anal ysis to maintain the study  
blind at the investigator site. Only  the investigator site staff and blinded study monitor, if 
assigned, will be blinded to study  treatment. A limited number of [COMPANY_007] study  team personnel 
will be unblinded to participant treatments in order to permit real -time interpretation of the 
safet y and PK data; and provide information necessary  to potent ially alter the dose escalation 
sequence. The blinded study  monitor, if assigned, will remain blinded to treatment until all 
monitoring for the stud y has been completed. Specimens from participants randomized to 
placebo will not be routinely  anal yzed. To m inimize the potential for bias, treatment 
randomization information will be kept confidential by  [CONTACT_825905] y reasons.
6.4. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and tim e of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF. 
Study  site personnel will examine each participant’s mouth to ensure that the study  
intervention was ingested.
6.5. Concomitant Therapy
Use of prescripti on or nonprescription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safety  or the overall results of the study may be permitted on a case -by-case basis 
following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses of 
≤1g/day .
Females using hormonal contraceptives or taking hormone replacement t herap y may be 
eligible to participate in this study  if they  are willing to discontinue therapy at least [ADDRESS_1145369] dose of study  treatment and remain off hormonal therap y for the duration of 
the study . Depo -Provera®must be discontinued at least [ADDRESS_1145370] dose of 
study  treatment. Hormonal contraceptives that meet the requirements of this study  are 
allowed to be used in participants who are WOCBP (See Appendix 4 ).

PF-[ADDRESS_1145371] dose of study  intervention 
will be documented as concomitant treatments.
6.5.1. Rescue Medicine 
There is no rescue therapy to reve rse the AEs observed with study  intervention; standard 
medical supportive care must be provided to manage the AEs. 
6.6.
Dose Modification
Progression to the next dose in PART- [ADDRESS_1145372] 
1placebo
-treated participant dosed in the previous dose -level.
6.6.1. Dose Escalation and Stoppi[INVESTIGATOR_705093]. Dose escalation may  be stopped if it is determined that the limits of safety  
and/or tolerability  have been reached. This decision will be made after a discussion takes 
place between the sponsor study  team and the investigator. The sponsor study  team may  not 
overrule the investigator’s decision to stop dose escalation. If dose escalation is stopped 
because of an y of these criteria, additional cohorts may receive the same or lower doses of 
the study  intervention .
The dose escalation will be terminated based on the following criteria:
If 50% or more of the participants receiving active drug at a given dose level (but not 
participant sreceiving placebo) deve lop similar clinically  significant laboratory , ECG, 
or vital sign abnormalities, in the same organ class, indicating dose- limiting 
intolerance .
Severe nonserious AEs,considered as, at least, possibly  related to study  intervention
administration, in 2participants at a given dose level (but not participants receiving 
placebo), independent of within or not within the same system organ class, indicating 
dose-limiting intolerance .

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 75•Dosing will be paused for any SAE that occurs in a participant receiving active 
treatment until causality is fully assessed by [CONTACT_978] [INVESTIGATOR_38107]. Dosing may resume if the SAE is determined to be not drug-related by [CONTACT_978] [INVESTIGATOR_38107]. If the SAE is determined to be either drug-related or unknown, either dosing will cease or the SAE will be evaluated by [CONTACT_456]’s protocol review committee (or similar review group), which is independent of the study team and investigators. If the protocol review committee determines that dosing may resume, a plan that mitigates risks to participants with the resumption of dosing will be implemented. Such a plan could include a revision of inclusion/exclusion criteria, repeating or reducing the dose, or adding appropriate safety monitoring.
•It is determined that the limit of safety and/or tolerability has been reached. This 
decision will be made following discussions between the study team and the investigator.
•Other findings that, at the discretion of the study team and investigator, indicate that 
dose escalation should be halted.
•If, at any dose level, the average exposure reaches or exceeds the PK stoppi[INVESTIGATOR_705089], 
total plasma AUC (AUC
infi n  P A R T - 1a n d  P A R T - 5a n d  A U C tauin PART-2) and C max
of μg•h/mL and μg/mL.  
•If, based on the observed data, the group mean C maxor AUC (based on total plasma 
concentration) of the next planned dose is projected to exceed the escalation limits, that dose will not be explored. Modified doses may be explored if they are not expected to exceed PK stoppi[INVESTIGATOR_3418].
Progression to the next dose will occur if the last dose was well tolerated and after 
satisfactory review of the available safety and PK data.
6.7. Intervention After the End of the Study
No intervention will be provided to study participants at the end of the study.
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study InterventionIn rare instances, it may be necessary for a participant to permanently discontinue study 
intervention (definitive discontinuation). Reasons for definitive discontinuation of study intervention include the following 
•AE requiring discontinuation in investigator’s view;
•Pregnancy;CCI CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 76Positive COVI D-[ADDRESS_1145373] be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -up, 
and/or f uture collection of additional information.
ECG Changes 
A participant who meets either bulleted criteria based on the average of triplicate ECG 
readings will be withdrawn from the stud y intervention. 
QTc, QTcB, QTcF >500 msec.
Change from baseline: QTc > 60 msec.
If a clinically  significant finding is identified (including, but not limited to ,changes from 
baseline in QT cFafter enrollment ), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any change in participant management is 
needed. This review of the ECG printed at the time of collection must be documented. An y 
new clinicall y relevant finding should be reported as an AE.
Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent wit h presence or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney  injury , are considered potential 
cases of acute kidney  injury  and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 µmol/L ) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥26.5 µmol/L ] in SCr
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µmol/L ), the 
participant should be discontinued from the stud y and adequate, immediate, supportive 
measures taken to correct apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include laboratory  tests, de tailed history , and phy sical 
assessment. In addition to repeating SCr, laboratory tests should include serum BUN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 77phosphate/phosphorus, and calcium), in addition to ur inary  dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abnormalities 
identified, should be considered potential cases of drug- induced kidney  injury  irrespective of 
availability  of all the results of the investigations performed to determine etiology  of the 
abnormal SCr. If ≥2healthy  participants in a given period in PART -[ADDRESS_1145374] 2 consecutive SCr results of ≥0.3 mg/dL (or 
≥26.5 µmol/L ), an assessment of whether the finding may  be considered an adverse drug 
reaction should be undertaken.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the stud y at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] ;
Investigator’s decision;
Pregnancy .
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early discontinuation visit applies only  to participants who are enrolled/randomized and 
then are prematurely  withdrawn from the study . Participants should be questioned regarding 
their reason for withdrawal. 
The participant will be permanentl y discontinued both from the study intervention and from 
the study  at that time.
If a participant withdraws from the study , he/she may  request destruction of any  remain ing 
samples taken and not tested, and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The spon sor may  retain and continue to use any  data 
collected before such withdrawal of consent.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 78Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was prese rved.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_78258]. Participants should notify  the investigator in writing of the decision to withdraw 
consent from future follow -
up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study interventi on or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to de termine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol low-up 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for/attend a 
required stud y visit:
The site must attempt to contact [CONTACT_288949]/or 
should continue in the study .
Before a parti cipant is deemed lost to follow -
up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medic al record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures. 
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.

PF-[ADDRESS_1145375] reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration mee t eligibility  criteria.
A participant who qualified for this protocol but did not enroll from an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility  criteri a for this study . In 
addition, other clinical assessments or specimen collections, eg, banked biospecimens, may  
be used without repeat collection, as appropriate.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol- required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood samp ling volume for individual participants in this study  may  be up to
approximately  480 mL, 290 mL, 160 mL, 205 mLand 485mLin PART -1, PART -2,
PART -
3,PART - 4 and PART -5, respectively . The actual collection times of blood sampling 
may change. Additional blood samples may  be taken for safet y assessments at times 
specified b y [COMPANY_007], provided the total volume taken during the stud y does not exceed 550 mL 
during an y period of 60 consecuti ve day s.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 80To prepare for stud y participation, participants will be instructed on the information in the 
Lifesty le Considerations and Concomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
No efficacy  assessment is planned in this study .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, n ose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and 
participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. 
Participant s must remove shoes, bulky  layers of clothing, and jackets so that only  
light clothing rema ins. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
8.2.2. Vital Signs
Supi[INVESTIGATOR_78235]’s arm supported at the level of the heart, and 
recorded to the nearest mm Hg after approxim ately [ADDRESS_1145376]. The same arm 
(preferabl y the dominant arm) will be used throughout the study . Participants should be 
instructed not to speak during measurements.  
The same properl y sized and calibrated BP cuff will be used to measure BP each time . The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery
 for at least 
30 seconds. When the timing of these measurements coincides with a blood col lection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection. 
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary , to ensure appropriate collection of safety  data.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Respi[INVESTIGATOR_769072]  5minutes of rest in a supi[INVESTIGATOR_422091] [ADDRESS_1145377] and before BPmeasurement.
[IP_ADDRESS]. Temperature
Temperature will be measured orally.  No eating, drinking, or smoking is allowed for 
[ADDRESS_1145378] 12-l ead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex. Alternative lead placement methodology  using torso leads (eg, Mason- Likar) is not 
recommended given the potential risk of discrepancies with ECGs acquired using standard 
limb lead placement. All scheduled ECGs should be performed after the participant has 
rested quietly for at least 10 minutes in a supi[INVESTIGATOR_2547]. 
In PART -1and PART -5, triplicate 12 -lead ECGs will be obtained approximately  2 to 
4
minutes apart; the average of the triplicate ECG measurements collected before dose 
administration on Day 1 of each period will serve as each participant’s baseline QTc value. 
In PART -2, triplicate 12 -lead ECGs will be obtained approximately  2 to 4 minutes apart; the 
average of the triplicate ECG measurements collected at ea ch nominal time point on Day 1 in 
MAD cohorts will serve as each participant’s time
-controlled baseline QTc value. 
To ensure safet y of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) the mean 
value from the triplicate measurements for an y postdose QTc Finterval is increased by  
≥60msec from the baseline andis >450 msec; or b) an absolute QTc Fvalue is ≥[ADDRESS_1145379] hourly  until QTc Fvalues from 2 successive ECGs fall below the 
threshold value that triggered the repeat measurement.
For PART -3and PART -4only (when Single ECGs are conducted ): To ensure safet y of 
the participants, a qualified individual at the investigator site will make comparisons to 
baseline measurements. Additional ECG monitoring will occur if a) a postdose QTc interval 
is increased b y ≥60msec from the baseline andis >450 msec ; or b) an absolute QTc value is 
≥[ADDRESS_1145380] hourly  until QTc values from 2 successive ECGs 
fall below the threshold value that triggered the repeat measurement.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 82If a) a postdose QTc interval remains ≥60msec from the baseline and is >450 msec; or b) an 
absolute QTc value is ≥500 msec for an y scheduled ECG for greater than 4 hours (or sooner, 
at the discretion of the investigator); or c) QTc intervals get progressi vely longer, the 
participant should undergo continuous ECG monitoring. A cardiologist should be consulted 
if QTc intervals do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTc values are in the 
acceptable range.
ECG values of potential clinical concern are liste d inAppendix 7.
[IP_ADDRESS]. Continuous Cardiac Monitoring by [CONTACT_336258] (PART -1and PART -5only)
All abnormal rh ythms will be recorded and reviewed by  [CONTACT_638795]. T he time, duration, and description of the clinicall y 
significant event will be recorded in the CRF. In addition, a printed record of the tracing(s) of 
the clinically  significant rhy thm(s) will be made and retained with other source documents.
Telemetry  should be collected using a centralized sy stem that also allows for the storage and 
advanced anal ysis of all recorded data in order to preserve important events for future 
evaluations. Holter monitoring should not be used in parallel with continuous telemetry , 
unless it is the only  means of data storage available at the investigator site, or verifiable 
arrhythmia quantification is required. To establish a baseline, telemetry  should be recorded 
for at least [ADDRESS_1145381] any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 83the underl ying disease, unless judged by  [CONTACT_78259]'s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or wi thin48hafter the last dose of study  intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline w ithin a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -up assessments in the event of potential 
drug-induced liver injury.
Participant s may  undergo random urine drug testing at the discretion of the investigator. 
Drug testing conducted prior to dosing must be negative for participant s to receive study  
intervention . 
8.2.5. Pregnancy Testing 
Pregnancy  tests may  beurine or serum tests, but must have a sensitivity  of at least 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA . 
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant’s receiving the stud y treatment. Pregnancy  tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment p eriod (or when potential 
pregnancy  is otherwise suspected) and at discharge. Pregnancy  tests may  also be repeated if 
requested b y IRBs/ECs or if required b y local regulations.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3.
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
The investigator and an y qualified d
esignees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy  intervention (see Section 7.1). 
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 848.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participati on in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of 28calendar days after the last administration of the study  intervention .
Follow -up by  [CONTACT_340757] a level acceptable to the 
investigator and [COMPANY_007] concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant definitivel y discontinues or temporarily discontinues stud y intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek AE or SAE after the partici pant has concluded 
study  participation. However, if the investigator learns of any  SAE, including a death, at an y 
time after a participant has completed the study , and he/she considers the event to be 
reasonabl y related to the study  intervention, the investigator must promptl y report the SAE to 
[COMPANY_007] using the CT SAE Report Form .
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_1145382] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3.The investigator will submit any  updated SAE data to the sponsor within 
24
hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_1145383] on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 858.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow
-up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRB s/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing of SAEs) from the sponso r will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study  intervention under stud y during pregnancy  or breastfeeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception . 
A female is found to be pregnant while being exposed or having been ex posed to 
study  intervention due to environmental exposure. Below are examples of 
environmental exposure during pregnancy : 
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262], inhalation, or skin 
contact.
A male famil y member or healthcare provider who has been exposed to the study 
intervention by  [CONTACT_78262], inhalation, or skin contact [CONTACT_240854]. 
The invest igator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to 
[COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details o f the 
pregnancy  will be collected after the start of study  intervention and until [ADDRESS_1145384] dose. 
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form a nd EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -
up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 87Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_1145385] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  relate d to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -
up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental dela ys). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_78262], inhalation or skin c ontact. 
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the stud
y, so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is ma intained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact [CONTACT_19994] , which may  ormay not lead to the occurrence of an AE. Such persons may  
include healthcare providers, famil y members, and other roles that are involved in the trial 
participant’s care.
The investigator must report occupational exposure to [COMPANY_007] Safet y within 24 hours of the 
investigator’s awareness regardless of whether there is an associated SAE. The information 
must be reported using the CT SAE Report Form. Since the information does not pertain to a 
participant enrolled in the study , the information is not recorded on a CRF; however, a cop y 
of the completed CT SAE Report Form is maintained in the investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable .
8.3.8. Adverse Events of Special Interest
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.3.[ADDRESS_1145386] SAE Report Form.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not applicable .
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical tr ial settings, such as 
medication errors.

PF-[ADDRESS_1145387] SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a study  participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE page of the 
CRF.
Medicat ion errors should be reported to [COMPANY_007] Safety  within [ADDRESS_1145388] SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of 
PF-07321332 greater than 3000 mg within a 24-hour [-2 hour]
time period will be considered an overdose.
Sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_44686] m onitor within 24 hours .
2.Closely  monitor the participant for an y AEs/SAE sand laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of study  intervention 
(whichever is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Safety  only when associated with a nSAE.

PF-[ADDRESS_1145389] dose of 
study  intervention if requested by  [CONTACT_7195] (determined on a case -by-case 
basis). 
Decisions regarding dose interru ptions or modifications will be made by  [CONTACT_177266] m edical m onitor based on the clinical evaluation of the participant.
8.5.Pharmacokinetics 
8.5.1. Plasma for Analysis of PF -07321332 PK, 19F-NMR measurement and Metabolic 
Profiling
Blood samples of approximately  4mL, to provide a pproximately 1.5mLof plasma , will be 
collected 
for measurement of plasma concentrations of PF-07321332 as specified in the SoA. 
In PART -2 MAD portion of the study conducted at NHCRU only, exploratory  
microsampling PK blood samples for the measurement of PF -07321332 concentrations may  
be collected in order to evaluate one or more approach (es). Total blood volume for 
exploratory  microsampling PK will not exceed 0. 4mL at each time point specified in the 
SoA.In Cohort 1, Period 2 in PART -1 and PART - 2 of the stud y, blood samples of 
approximately  6mL, to provide a minimum of 2 mL of plasma , may becollected for 
19F-NMR measurement of drug related m aterials and/ormetabolic profiling as specified in 
the SoA .In PART -4, 10 mL  blood samples will be collected for metabolite identification as 
specified in 
the SoA . Instructions for the collection and handling of biological samples will 
be provided in the lab oratory manual or by  [CONTACT_456]. The actual date and time (24 -hour 
clock time) of each sample will be recorded.
The actual times may  change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 - minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF. Collection of samples more than 10 hours after dose
administration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF.
Samples collected for analy ses of PF -07321332 concentration may  also be used to evaluate
safet y or efficacy aspects related to concerns arising during or after the study, for metabolite 
identification and/or evaluation of the bioanal ytical method, or for the measurement of 
ritonavir or for other internal exploratory  purposes.
Genetic anal yseswill not be performed on these plasma samples unless consent for this was 
included in the informed consent. Participant confidentiality  will be maintained.
Samples collected for measurement of plasma concentrations of PF-[ADDRESS_1145390] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit yhas been compromised.
Drug concentration information that would unblind the study will not be reported to 
investigat orsites or blinded personnel until the respective cohort of study  has been 
unblinded.
Any changes in the timing or addition of time points for an y planned stud y assessments must 
be documented and approved by  [CONTACT_185618], but will not constitute a protocol amendment. The I RB/EC will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme or 
amendment of the ICD.
8.5.2. Urine Pharmacokinetics (PART -2 only)
Urine samples will be collected for an interval as specified in the SoA and mixed thoroughly  
and the total volume will be measured and recorded on the CRF. An aliquot of 5mL will be 
collected for the measurement of urine concentrations of PF
-07321332. Instructions for the 
collection and handling of biological samples will be provided in the laboratory  manual or by  
[CONTACT_456]. The actual date and time (24 -hour clock time) of start and end of each collection 
interval will be recorded.
The urine blank (approximately  5mL)for PK will be obtained prior to dosing .
Samples collected for measurement of urine concentrations of PF -[ADDRESS_1145391] be processed and shipped as indicated in the instructi ons provided to 
the investigator site to maintain sample integrity . Any  deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented a nd reported to the sponsor. 
On a case b y case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised.
Drug concentration information that would unblind the study
 will not be reported to 
investigator sites or blinded personnel until the respective cohort of the study  has been 
unblinded.

PF-[ADDRESS_1145392] 
be documented and approved by  [CONTACT_185618], but will not constitute a protocol amendment. The I RB/EC will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme or 
amendment of the ICD.
As part of understanding the pharmacokinetics of t he study  drug, samples may  be used for 
metabolite identification and/or evaluation of the bioanaly tical method. These data will be 
used for internal exploratory purposes and will not be included in the CSR. 
8.5.3. Urine and Feces for Measurement of Drug -Related Material by 19F-NMR and 
Metabolic Profiling (PART -1: Cohort -1, Period 2 only)
Urine will be collected in Cohort 1, Period 2 of PART- 1 for determination of total drug 
related material b y 19F-NMR spectroscop y and metabolite profiling as specified in the SoA. 
The participants will force void before oral dosing. Prior to dosing on Day  1 (within 
24hours), each participant must empty  his urinary  bladder; an aliquot from this urine will 
serve as the “urine blank”. The details regarding the collection, processing, storage and 
shippi[INVESTIGATOR_825887] . 
Feces will be collected for determination of total drug related material b y 19F-NMR 
spectroscop y and metabolite profiling as specified in the SoA. If possible, a pre -dose fecal 
sample within 48 hours prior to dosing should be collected.
Details of the collection of aliquots, volume, processing, storage and s hippi[INVESTIGATOR_705097] . The 
actual date and time (24 -hour clock time) of each sample will be recorded.
At the discretion of the Sponsor, one or more assessments on urine and feces may  not be 
conducted if deemed unnecessary  by [CONTACT_1034].  
8.5.4. Urine and Feces for Measurement of Drug -Related Material and Metabolic 
Profiling (PART -4 only)
Urine will be collected in PART -
4for determination of total drug -related material and 
metabolit e profiling as specified in the SoA. The participants will force void before oral 
dosing. Prior to dosing on Day  1 (within 24 hours), each participant must empty  his urinary  
bladder; an aliquot from this urine will serve as the “urin e blank”. The details regarding the 
collection, processing, storage and shippi[INVESTIGATOR_825888] . 
Feces will be collected for determination of total drug- related material and metabolite 
profiling as specified in the SoA. Apre-dose fecal sample within 48 hours prior to 
PF-
07321332 dosing is required before dosing drug .

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 93Details of the collection of aliquots, volume, processing, storage and shippi[INVESTIGATOR_705097]. The actual date and time (24-hour clock time) of each sample will be recorded.
At the discretion of the Sponsor, one or more assessments on urine and feces may not be 
conducted if deemed unnecessary by [CONTACT_1034].  
8.6. Pharmacodynamics
Pharmacodynamic parameters are not evaluated in this study.
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 948.9. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.10. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
 
 
 
 
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
There are no statistical hypotheses for this study.
9.2. Sample Size Determination
A total of up to 78 participants (12 in PART-1: SAD, up to 30 [with 2 cohorts and 3 optional 
cohorts] in PART-2: MAD, a maximum of 18 in PART-3: Relative Bioavailability /Food 
Effect cohort,6 in PART-4: metabolism and excretion and up to 12 in PART-5: Supratherapeutic Exposure) are planned to be randomized in this study. Participants who 
discontinue for reasons other than safety during the study may be replaced at the discretion of the sponsor and Investigator.
9.2.1. PART-1: SAD
A sample size of 6 participants per cohort for this single, dose-escalating, 4-period 
cross-over, with placebo substitution study (4 active, 2 placebo per dose level) has been chosen based on the need to minimize first exposure of healthy participants to a new 
chemical entity and the requirement to provide adequate safety and toleration information
and PK information at each dose level.CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 959.2.2. PART -2: MAD
A sample size of 6participants per cohort, with [ADDRESS_1145393] su fficient participants 
randomized to provide adequate safet y and toleration information and PK. 
This sample size has been judged sufficient to obtain a preliminary  evaluation of safet y, 
tolerability ,and PK data in these populations.
9.2.3. PART -3: Relative Bioavailability /Food Effect
A sample size of up to 18 participants will provide adequate precision to compare the relative 
bioavailability  of a tablet formulation of PF -07321332 relative to oral suspension
. This 
sample size assumes that the within- participant SD for log -transformed PK parameters would 
not increase beyond approximately  0.3. The expected widths of the 90% CIs with 
80% coverage probability  for the comparison of tablet formulation of PF -0732133 2 relative 
to oral suspension are shown in Table 11 for a range of possible effects. The sample size 
ultimately  decided for Relative Bioavailabilit y, by[CONTACT_456], will depend on observed 
variability  in plasma PK observed in PART -1: SAD.
Table 11. Probable 90% CI with 80% coverage probability for Varying SDs, Effect 
Sizes and Sample Sizes 
–in PART -3: Relative Bioavailability
EffectSize SD = 0.2 SD = 0.3
N = 12 N = 18 N = 12 N = 18
0.75 0.64 –0.88 0.66 –0.85 0.59 –0.95 0.62 –0.90
1.0 0.85 –1.17 0.88 –1.13 0.79 –1.27 0.83 –1.20
1.25 1.07 –1.46 1.10 –1.41 0.99 –1.58 1.04 –1.51
9.2.4. PART -4: Metabolism and Excretion
A sample size of approximately  6 participants (with at least 4 completers) is chosen based on 
the industry  standard sample size for metabolism and excretion studies. This sample size was 
not justified by  [CONTACT_705108][INVESTIGATOR_825889] h ypothesis testing criteria.
9.2.5. P ART -5: Supratherapeutic Exposures
A sample size of up to 12 participants (with at least 10 completers) is chosen based on the 
need to provide adequate safet y,tolera bilityand PK information at each dose level and/or 
administration schedule. At the discretion of the sponsor and investigator, participant who 
were enrolled in PART -2 may  be enrolled in PART -5.  

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 969.3.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Enrolled /Randomly  
assigned to stud y 
intervention"Enrolled" means a participant's, agreement to participate in a 
clinical study  following completion of the informed consent 
process. Potential participants who are screened for the 
purpose of determining eligibilit y for the stud y, but do not 
participate in the stud y, are not considered enrolled, unless 
otherwise specified b y the protocol.
Evaluable All participants randomly  assigned to study  intervention and 
who take at least 1dose of study  intervention for the given 
part of the stud y.
Safety All participants randomly  assigned to study  intervention and 
who take at least [ADDRESS_1145394] completed drug related material
concentration (urinary  and fecal) data and who had no 
protocol deviations that may  have affected the mass balance 
analysis.
9.4. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.4.1. General Considerations
The data from each part of the study will be anal yzed and reported separately  in a single CSR 
issued at the end of this study . 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 979.4.2. Primary Endpoint(s)
The primary  endpoints in PART -1,PART - 2 and PART - 5 are related to safety /tolerability  
with analy ses as described in Section 9.4.5. 
The primary  endpoints in PART -3are the plasma PK endpoints whose analyses are described 
in Sections [IP_ADDRESS] and [IP_ADDRESS].
The primary  endpoints in PART -4 are percent recovery  and cumulative recovery  of 
drug-related material in urine, feces determined based on total administered dose. Percent 
recovery  of drug
-related material in u rine and feces will be determined based on total 
administered dose. The total recovery  of drug-related material in urine and feces and their 
combination will be listed and summarized. 
9.4.3. Secondary Endpoint (s)
The secondary  endpoints in PART -1,  PART - 2 and PART - 5 as well as the primary  endpoints 
in PART -3 related to PK are described herein. 
[IP_ADDRESS].
PKAnalysis
[IP_ADDRESS].1. Derivation of PK Parameters
Plasma PK parameters for PF ‑0732332 will be derived (if data permit) from the 
concentration -time data using standard noncompartmental methods following a single oral 
dose ( Table 12 ) and multiple oral doses ( Table 13). Urine PF‑07321332 PK parameters are 
described in Table 13.Actual PK sampling times will be used in the derivation of PK 
parameters. In the case that actual PK sampling times are not available, nominal PK sampling 
time will be used in the derivation of PK 
parameters.
Table 12. Plasma PF ‑07321332 PK Parameters For PART -1: Single Ascending 
Doses , PART -
3:Relative Bioavailab ility/Food Effect , PART -4: 
Metabolism and Excretion and PART- 5: Supratherapeutic Exposure
Param eter Part of The 
StudyDefinition Method of Determ ination
AUC lastb1, 3, [ADDRESS_1145395] quantifiable concentration (C last)Linear/Log trapezoidal method
AUC infa1, 3, [ADDRESS_1145396]+ (C last*/k el),
where C last* is the predicted 
plasma concentration at the last 
quantifiable time point from the 
log-linear regression analysis
Cmax 1, 3, [ADDRESS_1145397] occurrence
t½a1, 3, 5 Term inal half -life Log e(2)/k el, 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 98where k elis the terminal phase 
rate constant calculated by a 
linear regression of the log -linear 
concentra tion-time curve. Only 
those data points judged to 
describe the terminal log -linear 
decline are used in the regression.
CL/Fa1, 3 Apparent clearance Dose/AUC inf
Vz/Fa1, 3 Apparent volume of distribution Dose/(AUC inf• kel)
AUC last(dn) 1, [ADDRESS_1145398]/Dose
AUC inf(dn)a1, 3 Dose normalized AUC inf AUC inf/Dose
Cmax(dn) 1, 3 Dose normalized C max Cmax/Dose
a.If data permit.
b.In PART -3, pre-dose (0h) sample from Period s2 and 3 w ill also be considered as 48h PK sample for 
Period s1 and 2, respectively. 
dn=dose normalized to a 1 mg dose .

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 99Table 13. Plasma and Urine PF ‑07321332 PK Parameters for PART -2: Multiple 
Ascending Doses
Param eter Day(s) Definition Method of Determ ination
Plasm a
AUC τ 1, 5, 10 Area under the plasma concentration -
time profile from time zero to time tau 
(τ), the dosing interval, where τ= 8 for 
TID dosing or 12 hours for BID dosingLinear/Log trapezoidal method
Cmax 1, 5, [ADDRESS_1145399] occurrence
Cmin 5, 10 Minimum observed concentration 
during the dosing intervalObserved directly from data
PTR 5, 10 Peak -to-trough ratio Cmax/Cmin
Rac 5, 10 Observed accumulation ratio for AUC τ Day 5 or Day 10 AUC τ/Day 1 AUC τ
Rac,Cmax 5, 10 Observed accumulation ratio for C max Day 5 or Day 10 C max/Day 1 C max
CL/F 5, 10 Apparent clearance Dose/AUC τ
t½a10 Term inal half -life Log e(2)/k el, 
where k elis the terminal phase rate 
constant calculated by a linear 
regression of the log -linear 
concentration -time curve. Only those 
data points judged to describe the 
terminal log -linear decline are used in 
the regression
Vz/Fa10 Apparent volume of distribution Dose/(AUC τ• kel)
AUC τ(dn) 1, 5, 10 Dose normalized AUC τ AUC τ/Dose
Cmax(dn) 1, 5, 10 Dose norm alized C max Cmax/Dose
Urine
Aeτ 10 Amount excreted in urine as unchanged 
drug over the dosing interval τSum of (urine volume ×urine 
concentration) for each collection over 
the dosing interval 
Aeτ% 10 Percent of dose excreted in urine as 
unchanged drug over the dosing interval 
τ100 * Ae τ/Dose
CL r 10 Renal clearance Aeτ/AUC τ
a.If data permit.
dn=dose normalized to a 1 mg dose .
[IP_ADDRESS]. Statistical Methods for PK Data
No formal inferential statistics will be applied to the plasma PK data apart from the 
comparisons of formulation and food effect in either Part 1 orPart 3.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 100For all parts of the study , plasma concentrations will be listed and summarized descriptively  
by [CONTACT_306917]. Individual participant and median profile s of the 
concentration -time data will be plotted by  [CONTACT_3148]. For summary  statistics and median plots 
by [CONTACT_31065], the nominal PK sampling time will be used, for individual participant plots 
by [CONTACT_5586], the actual PK sampling time will be used for plasma samples. Median profiles will 
be presented on both linear -linear and log -linear scales.
The plasma PK parameters listed in Table 12 and Table 13 will be summarized descriptively  
by [CONTACT_2715].
For PART -1,PART - 2 and PART -5, dose normalized (to 1 mg) AUC infor AUC tauand C maxof 
PF-
[ADDRESS_1145400] dose (using a logarithmic s cale) and will include 
individual participant values as well as the geometric means for each dose. These plots may
be used to help understand the relationship between the PK parameters and dose. 
For PART -
2, urine amounts as listed in Table 13of PF -[ADDRESS_1145401], Cmax, and AUC inf(if data permit) for 
PF-[ADDRESS_1145402].
Estimates of the adjusted mean differences (Test -Reference) and corresponding 90% CIs will 
be obtai ned from the model. The adjusted mean differences and 90% CIs for the differences 
will be exponentiated to provide estimates of theratio ofadjusted geometric means
(Test/Reference) and 90% CI s for the ratios.
Thefollowing comparisons willbemade:
Comparison Test Reference
Formulation PF-07321332 tablet formulation in fasted 
state (B)PF-07321332 oral suspension in fasted state (A)
Food Effect PF-07321332 tablet formulation in fed 
(high fat meal) state (C)PF-07321332 tablet formulation in fasted state (B)
Additional specifications about the tables, listings, and figures will be outlined in the SAP.
9.4.4. Tertiary/Exploratory Endpoint(s)
Exploratory  endpoints may  not be reported in the CSR and may  be reported separately .  
9.4.5. Safety Analyses
[IP_ADDRESS]. Standard Safety Analyses
In this stud y, assessment of safet y and tolerability following single -and multiple -ascending 
doses forms the primary  objective for PART -1,PART - 2 and PART -5. In all 5parts of the 
study , all safety  anal yses will be performed on the Safety Analysis Set .

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 101All AEs, ECGs, BP, pulse rate, continuous cardiac monitoring, and safety laboratory data 
will be reviewed and summarized on an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and PE and neurological examination information, as applicable, collected 
during the course of the study will be considered source data and will notbe required to be 
reported, unless otherwise noted. However, any untoward findings identified on physical 
and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.
[IP_ADDRESS]. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTcF interval, PR 
interval, and QRS complex will be summarized by [CONTACT_22841].
The number (%) of participants with maximum post dose QTcF values and maximum 
increases from baseline in the categories outlined in Table 14 will be tabulated by [CONTACT_3148].
Table 14. Safety QTcF Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (msec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >[ADDRESS_1145403] unblinded reviews of the data during thecourse of the study  for the 
purpose of safet y assessment, facilitating dose escalation decisions, facilitating PK modeling, 
and/or supporting clinical development . Unblinded results will be reviewed by  a designated 
limited number of sponsor colleagues within the study  team.
9.6.Data Monitoring Committee or Other Independent Oversight Committee
This study  will not usea DMC.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CI OMS International Ethical Guidel ines;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_107095]/EC by  [CONTACT_107096]/EC before the study  is 
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes nece ssary  to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH gui delines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction im posed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be infor med immediately .  
In addition, the investigator will inform [COMPANY_007] immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participant
s against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH G CP that the investigator becomes aware 
of.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant  and answer all questions regarding the study .The participant should be given 
sufficient time and opportunity  to ask questions and to decide whether or not to participate in 
the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requi rements of 21 CFR 50, 
local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the shar ing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be us
ed by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct hi
s or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant.
A participant who is rescreened is not required to sign another IC Difthe rescreening occurs 
within 10days from the previous I CDsignature [CONTACT_568].
For NH CRU only:unless prohibited by  [CONTACT_20006]/EC decision, t he IC D
will contain a separate section that addresses the use of samples for optional additional
research. The optional additional research does not require the collection of any  further 
samples. The investigator or authorized designee will explain to each parti cipant the 
objectives of the additional research. Participants will be told that they  are free to refuse to 
participate and may  withdraw their consent at an y time and for an y reason during the storage 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 105period. A separate signature [CONTACT_22862] a participant's agreement to allow 
specimens to be used for additional research. Participants who decline to participate in this 
optional additional research will not provide this separate signature .
10.1.3. Data Protection
All parties will comply  with all appl icable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropri ate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. An y 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant- specifi c code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record identification . In 
case of data transfer, the sponsor will pr otect the confidentiality  of participants’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.4. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posti ng the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study results outside of the require ments of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].

PF-[ADDRESS_1145404] for [COMPANY_007] -sponsored interventional studies in 
accordance wi th the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensio ns and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data Sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the sci entific understanding of the 
disease, target, or compound class. [COMPANY_007] will make available data from these trials 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.5. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
The investigator must maintain accurate docum entation (source data) that supports the 
information entered in the CRF.

PF-[ADDRESS_1145405] ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, ris k-based initiatives in operations and quality  
such as risk management and mitigation strategies and analytical 
risk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the IQMP.
The sponsor or designee is responsible for the data management of this study ,including 
quality  chec king of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants a re being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  requirements.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the writt en approval of the sponsor. No records may  be 
transferred to another location or part
y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When partic ipant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.

PF-[ADDRESS_1145406] participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of th e sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site cl osure at any  time upon notification to the sponsor if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.

PF-[ADDRESS_1145407] will control as to termination rights.
10.1.8. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publ ication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information befo re disclosure, except for any  study -or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the stud y, the investigator will compl y with recog nized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for publication of the over all study  results 
covering all i nvestigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_9231].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical s tudy agreement, the publication policy  set out in 
this section will not apply.
10.1.9. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately
 qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_4111] l ocated in the CTMS . 
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participant s are provided with a contact [CONTACT_20016] . The contact [CONTACT_4662], at a minimum, protocol and study  intervention identifiers, 
participant numbers, contact [CONTACT_22850], and contact [CONTACT_4664] a 
contact [CONTACT_825906] a medical question or problem originating from another healthcare professional not 
involved in the participant ’s participation in the study . The contact [CONTACT_825907] m edical questions or problems; however, it 

PF-[ADDRESS_1145408] number is not intended for use by  [CONTACT_825908] ,and if a participant calls that number, he or she will be directed back to the 
investigator site.

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 15. Protocol -Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
HematocritRBC count
MCV
MCHMCHCPlatelet countWBC count
Total neutrophils (Abs)
Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN and creatinine
Glucose (fasting)Calcium
Sodium
PotassiumChlorideTotal CO
2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphataseUric acidAlbuminTotal proteinpH
Glucose (qual)Protein (qual)
Blood (qual)
KetonesNitritesLeukocyte esteraseUrobilinogen
Urine bilirubin
Microscopy
a•Urine drug screeningc
•SARS-CoV-2 RT-PCR
•eGFR [CKD EPI]
•Pregnancy test ( β-hCG)d
•aPTT
•PT-INR
•Fibrinogen
•TSH
•Free T4
At screening only:
•FSHb
•Hepatitis B surface 
antigen
•Hepatitis B surface 
antibodye
•Hepatitis B core antibody
•Hepatitis C antibody
•Human 
immunodeficiency virus
a.Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
b.For confirmation of postmenopausal status only, at screening only.
c.The minimum requirement for drug screening includes cocaine, THC, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], 
and amphetamines (others are site and study specific).
d.Serum or urine β-hCG for female participants of childbearing potential.
e.Can be done either automatically or only if HBcAb or HBsAg is positive, as per local practices.
Investigators must document their review of each laboratory safety report.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study.
 
 CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 112 CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator. Any abnormal laboratory test 
results that meet any of the conditions below must be recorded as an A E:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervent ion administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
interve ntion or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 114Events NOT Meeting the A E Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the conditi on that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detecte d at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , death 
due to p rogression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_216472], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurr ed or was necessary , the AE 
should be considered serious.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 115Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accide ntal trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deci ding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_402880]. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bro nchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
Suspected transmission via a [COMPANY_007] product of an infectious agent, pathogenic or 
non-pathogenic, is considered serious. The event may  be suspected from clinical 
symptoms or laboratory  findings indicating an infection in a patient exposed to a 
[COMPANY_007] product. The terms “suspected transmission” and “transmission” are 
considered s ynon ymous. These cases are considered unexpected an d handled as 
serious expedited cases by [CONTACT_20020]. Such cases are also 
considered for reporting as product defects, if appropriate.
10.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording adverse events on the CRF 
and for reporting serious adverse events on the CT SAE Report Form to [COMPANY_007] Safet y. 
These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) nonserious AEs; and 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 116(3)exposure to the study  intervention under stud y during pregnancy  or breastfeeding, and 
occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collecte d, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CR F Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeeding, and 
occupational exposureAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is 
not recorded.All (and EDP supplemental 
form for EDP)  
Note: I nclude all SAEs 
associated with exposure 
during pregnancy  or 
breastfeeding. Include all 
AEs/SAEs associated with 
occupational exposure.
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_825890] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The inve stigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 117Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed 
as severe should not be confused with a nSAE. Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event be fore the initial transmission of the SAE data to the sponsor .

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 118The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for reporting 
purposes, as defined by  [CONTACT_456] . In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this 
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This m ay include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator wil l provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 
of recei pt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 119The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is com pleted at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  repo rted SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent b y overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].4. Appendix 4: Contraceptive Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28daysafter the last dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual li festy le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent. 
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person.
I
naddition to male condom use, a highl y effect ive method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a failure 
rate of <1% per year), with low user dependency, as described below during the 
intervention period and for at least [ADDRESS_1145409] dose of study  intervention,
which corresponds to the time needed to eliminate any  reproductive safet y risk of the 
study  intervention(s) . The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.
The invest igator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluatio n should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanen t infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal s tate is defined as no menses for 12 months without an 
alternative medical cause. In addition, a
High FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HR T. 
Female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their HRT during the study .Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.

PF-[ADDRESS_1145410] Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion .
5.Vasectomized partner .
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The s permatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent (for WOCBP partners only) 
1.Combined (estrogen and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation.
Oral;
Intravaginal;
Transdermal;
2.Progestogen -only hormone contraception associated with inhibition of ovulation.
Oral;
Injectable.
3.Sexual abstinence.
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
One of the followin g effective barrier methods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 123Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 124 
 
 
 
 
 
 
 
 
 CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are t ermed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"suscept ible" to progressive and serious liver injury , commonl y referred to as DILI. 
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pi[INVESTIGATOR_216474]/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the sam e lab oratory sample). In rare instances, by [CONTACT_22858], 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that me et the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laborat ory abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. 
Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cas es to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition me ntioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-[ADDRESS_1145411]/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible , 
preferabl y within [ADDRESS_1145412] and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase. Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of b lood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology . A detailed history , including relevant information, 
such as review of ethanol, acetaminophen /paracetamol (either b y itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surger y, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample sfor acetaminophen /paracetamol drug and/or protein adduct levels may  be 
warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s l
aw) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abn ormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings Th at May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by≥60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’ duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 msec).
New -onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_1145413] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .
Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm ( heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR >40bpm to <100 bpm),and 

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 128monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (such as
torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the inv estigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not t o be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 129
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 130
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 131
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 132
CCI
PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 133
CCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
3CLpro3C-like protein
Abs absolute
ADE adverse device effect
AE adverse event
Aetau/Ae amount excreted in urine as unchanged drug over the dosing 
interval τ /tau
Aetau%/Ae % percent of dose excreted in urine as unchanged drug over the 
dosing interval
AESI adverse events of special interest
ALT alanine aminotransferase
API [INVESTIGATOR_825891] 24 area under the plasma concentration -time profile from time zero to 
the time 24 hours
AUC 24,ss area under the plasma concentration -time profile from time zero to 
the time 24 hours at steady  state
AUC inf area under the plasma concentration -time curve from time 0
extrapolated to infinite time
AUC inf(dn) dose normalized AUC inf
AUC last area under the plasma concentration time curve from time [ADDRESS_1145414](dn) dose normalized AUC last
AUC tau/AUC t area under the plasma concentration- time profile from time zero to 
time tau (τ), the dosing interval
AV atrioventricular
BA bioavailability
BBS Biospecimen Banking S ystem
BCRP breast cancer resistance protein
BE bioequivalence
-hCG beta-human chorionic gonadotropin
BID twice dail y
BMI body  mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
Cav average concentration

PF-07321332
Protocol C4671001Final Protocol Amendment 3, 24 June 2021
PFIZER CONFIDENTIAL
Page 135Abbreviation Term
Cb/Cp ratio blood to plasma ratio
Ceff efficacious concentration
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD EPI [INVESTIGATOR_705100]/F apparent clearance
CL r renal clearance
Cmax maximum plasma concentration
Cmax(dn) dose normalized C max
Cmin minimum plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID-[ADDRESS_1145415] clinical trial
CTCAE Common Terminology Criteria for Adverse Events
CTMS clinical trial management system
CYP cytochrome P450
DDI drug-drug interaction
DILI drug-induced liver injury
DMC Data Monitoring Committee
dHNBE differentiated normal human bronchial epi[INVESTIGATOR_825892]/dT rate of rise of left ventricular pressure
DR dosing regimen
DU dispensable unit
EC ethics committee
EC 50 half maximal effective concentration
EC 90 90% maximal effective concentration
ECG electrocardiogram
eCRF electronic case report form
EDP exposure during pregnancy
EDR extemporaneous dispensing record
eGFR estimated glomerular filtration rate
EMA European Medicines AgencyCCI
PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page 136Abbreviation Term
E/T early termination
EU European Union
EudraCT European Clinical Trials Database
FAMHP Federal Agency  for Med
FDA US Food and Drug Administration
FIH first-in-human
19F-NMR fluorine -19 nuclear magnetic resonance
FOB functional observational battery
FSH follicle -stimulating hormone
fu free fraction
F/U follow -up
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GLP Good Laboratory  Practice
HAE human airway epi[INVESTIGATOR_825893] B core antibody
HBsA b hepatitis B surface anti body
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HCVAb hepatitis C antibody
HED human equivalent dose
hERG human ether -a-go-go related gene
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency  virus
HLM human liver microsome
HPD hours post first dose
HR heart rate
HRT hormone replacement therap y
IB Investigator’s Brochure
IC50 inhibitory  concentration 50%
ICD informed consent document
ICH International Council for Harmonisation
ID identification
I/E inclusion/exclusion
IMP investigational medicinal product
IND Investigational New Drug 
INR international normalized ratio
IPAL Investigational Product Accountability  Log
IQMP Integrated Quality  Management Plan
IRB Institutional Review Board
IV intravenous
kel rate constant for terminal phase

PF-[ADDRESS_1145416]
LVP left ventricular pressure
MAD multiple ascending dose
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MD multiple dose
MDR1 multidrug resistance mutation 1
M&E Metabolism and Excretion
msec millisecond
N/A not applicable
Nab neutralizing antibodies
NH New Haven
NHP non-human primates
NIMP non-investigational medicinal product
NMR nuclear magnetic resonance
NOAEL no-observed -adverse -effect level
NTCP human sodium taurocholate co -transporting poly peptide
OATP organic anion transporting pol ypeptides
PBPK physiology  based pharmacokinetic
PCRU [COMPANY_007] clinical research unit
PD pharmacod ynamic(s)
PDE phosphodiesterase
PE physical examination
P-gp P-glycoprotein
PI [INVESTIGATOR_19959](s)
PL placebo
PT prothrombin time
PTR peak to trough ratio
PVC premature ventricular contraction/complex
QTc corrected QT
QTcB corrected QT ( Bazetts method)
QTcF corrected QT (Fridericia method)
qual qualitative
Rac observed accumulation ratio for AUC τ
Rac,Cmax observed accumulation ratio for C max
RBA/FE relative bioavailabilit y/food effect
RBC red blood cell

PF-[ADDRESS_1145417] deviation
stable disease (based on content)
SE supratherapeutic exposure
SmPC Summary  of Product Characteristics
SoA schedule of activities
SOP standard operating procedure
SRSD single -reference safet y document
S[LOCATION_003]R suspected unexpected serious adverse reaction
t½ terminal half -life
T4 thyroxine
TBili total bilirubin
TEAE treatment -emergent adverse events
THC tetrah ydrocannabinol
TID three times dail y
Tmax time for C max
TSH thyroid stimulating hormone
ULN upper limit of normal
US [LOCATION_002]
Vss volume at stead y-state
Vz/F apparent volume of distribution
WBC white blood cell
WHO World Health Organization
WOCBP woman of childbearing potential

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE].REFERENCES
1. WHO Situation Report 51. 11 March 2020 Available from: 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/situation -reports. 
Accessed: 29 March 2020.
2. Wu Z, McGoogan JM. Character istics of and important lessons from the coronavirus 
disease 2019 (COVID -19) outbreak in China: summary  of a report of 72,314 cases from 
the Chinese Center for Disease Control and Prevention. JAMA .2020;323(13):1239 -42.
3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, 
and outcomes among 5700 patients hospi[INVESTIGATOR_776747] D-19 in the [LOCATION_001] City  
area. JAMA .2020;323(20):2052-9.
4. Dochert y AB, Harrison EM, Green CA, et al. Features of 20 -133 [LOCATION_006] patients in 
hospi[INVESTIGATOR_148501] h covid-19 using the ISARIC WHO Clinical Characterisation Protocol: 
prospective observational cohort study . BMJ .2020;369:m1985.
5. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospi[INVESTIGATOR_9645] 
2019 novel coronavirus -infected pneumonia in Wuhan, China. JAMA .
2020;323(11):1061 -9.
6. Cummings MJ, Baldwin MR, Abrams D, et al. Epi[INVESTIGATOR_623] , clinical course, and 
outcomes of criticall y ill adults with COVID- 19 in [LOCATION_001] Cit y: a prospective cohort 
study . Lancet .2020;395([ZIP_CODE]):1763-70.
7. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with 
coronavirus disease 2019: retrospective stud y. BMJ .2020;368:m1091.
8. Mao L , Jin H, Wang M, et al. 
Neurologic manifestations of hospi[INVESTIGATOR_776765] 2019 i n Wuhan, China. JAMA Neurol. 2020;77(6):683 -90.
9. Mehta P, McAuley  DF, Brown M, et al. COVID -19: consider cy tokine storm 
syndromes and immunosuppression. Lancet .2020;395([ZIP_CODE]):1033-4.
10. Beigel JH, Tomashek KM, Dodd L E, et al. Remdesivir for the treatment of 
Covid -19 - preliminary  report. N Engl J Med. 2020:1 -12.
11. Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis for design of anti -SARS drugs. Science. 2003;300:1763-7.
12. Maronpot RR, Yoshizawa K, Ny ska A, et al. Hepatic enzy me induction: histopathology . 
Toxicol Pathol .2010;38 (5):776-95.
13. Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS- CoV -2 in 
golden hamsters. Nature .2020;583:834-8.

PF-07321332
Protocol C 4671001
Final Pr otocol Amendment 3 , 24 June 2021
PFIZER CONFIDENTIAL
Page [ZIP_CODE]. Day CW, Baric R, Cai SX, et al. A new mouse-adapted strain of SARS- CoV as a lethal 
model for evaluating antiviral agents in vitro and in vivo. Virology .2009;395:210 -22.
15. Pearson D, Garnier M, Luneau A, et al. 19F- NMR -based determination of the 
absorption, metabolism and excretion of the oral phosphatidy linositol-3- kinase (PI3K) 
delta inhibitor leniolisib (CDZ173) in healthy  volunteers. Xenobiotica .2019;49
(8):953-60.
16. Dorr P, Westby  M, Dobbs S, et al. Maraviroc ([LOCATION_006]-427,857), a potent, orally 
bioavailable, and selective small- molecule inhibitor of chemokine receptor CCR5 w ith 
broad -spectrum anti -human immunodeficiency  virus ty pe 1 activity . Antimicrob Agents 
Chemother. 2005;49(11):4721-32.
17. Reddy  MB, Morcos PN, Le Pogam S, et al. Pharmacokinetic/pharmacod ynamic 
predictors of clinical potency
 for hepatitis C virus nonnucleoside poly merase and 
protease inhibitors. Antimicrob Agents Chemother .2012;56(6):3144 -56.
18. Shen L , Peterson S, Sedaghat AR, et al. Dose -response curve slope sets class -specific 
limits on inhibitory  potential of anti- HIV drugs. Nat Med. 2008;14(7):7 62-6.
19. Ritonavir Single Reference Safet y Document (SRSD). 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf .
